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ABSTRACT
After the findings were reported for the Women’s Health Initiative (WHI) study in the past
decade, there has been a significant decline in the overall use of hormone replacement therapy (HRT)
among women. However, there are still millions of middle-aged, menopausal women in the U.S. who are
currently undergoing hormone therapy. Their reasons for continuing treatment include relief of severe
menopausal symptoms, aid in the management of osteoporosis and reduction in the risk of colon cancer
(Ness et al., 2005). The purpose of the following investigation was to evaluate the impact of HRT on the
central and peripheral auditory systems both during and after treatment. Over the course of the study,
hormone treatments were administered to female aging CBA/CaJ mice to observe what effects estrogen
(E) and progestin (P) have on the peripheral and central auditory systems. Female CBA/CaJ middle age
mice were ovariectomized and placed into 4 HRT groups (E, P, E+P and Placebo [Pb]). Hormone
treatment lasted 6 months followed by a recovery/washout period of 1 month.

During this time,

electrophysiology tests such as auditory brainstem responses (ABR) and ABR gap in noise (GIN) were
used to measure neural activity for the auditory nerve and brainstem. Distortion product otoacoustic
emission (DPOAE) testing was also implemented to assess the functional status of the outer hair cells
(OHC) and their ability to amplify sound in the cochlea. After 6 months of treatment, animals treated
with E exhibited the least amount of changes in ABR thresholds and ABR GIN amplitudes than any other
subject groups. Interestingly, P animals exhibited an abrupt increase in ABR thresholds only 3 months
after treatment; however, for ABR GIN amplitude levels a progressive reduction observed throughout the
study.

E+P and Pb animals showed signs of accelerated age-related hearing loss (ARHL) with

significantly elevated ABR thresholds and dwindling ABR GIN amplitude levels. No significant signs of
recovery were observed for any of the hormone groups. Therefore, in the present murine investigation,
the effects of HRT were long lasting.

vi

To further expand on the results obtained for the electrophysiology tests, molecular biology
experiments were performed to evaluate the expression of IGF-1R and FoxO3 in the cochlea during
hormone therapy, from both in vitro and in vivo perspectives. Both genes play significant roles in the
PI3K/AKT pathway and were specifically chosen because of their role in anti-apoptotic responses and
cell survival. It was hypothesized that E attenuates the effects of ARHL via the PI3K/AKT pathway by
up-regulating IGF-1R and FoxO3 to counteract the effects of oxidative stress in the aging mammalian
cochlea. qPCR experiments were performed with stria vascularis (SV) lateral wall cells extracted from
the cochlea of each animal in the hormone groups post-treatment (in vivo) and in SVK-1 cells treated with
HRT over various lengths of time (in vitro) to evaluate the expression levels of IGF-1R and FoxO3. Invivo experiments showed that the E-treated animals had significantly higher IG-1R levels compared to the
other subject groups after treatment was discontinued. Similarly, IGF-1R levels steadily increased for Etreated SVK-1 cells over the course of hormone therapy, compared to P and E+P cells.

FoxO3

expression, on the other hand, declined for all of the hormone-treated cells groups, relative to control
SVK-1 cells (in vitro), and no statistical differences were detected for FoxO3 levels among the posttreatment animals (in vivo). These findings indicate that there is cross talk between E and IGF-1R
involving the PI3K/AKT pathway, which contributes to the delayed onset of ARHL observed during HRT
with E. Meanwhile, FoxO3 may not play a role in neuro-protective properties in the cochlea during HRT,
as initially hypothesized.

vii

CHAPTER ONE
INTRODUCTION
Scientists and clinicians have been assessing the benefits as well as the risks of hormone
replacement treatment (HRT) over the past decade. Studies such as the Woman’s Health Initiative (WHI)
and Heart and Estrogen-Progestin Replacement Study (HERs) have evaluated the effects HRT has on
blood pressure, breast cancer, cervical cancer, osteoporosis, stroke and heart disease for menopausal
women. Consequently, the controversial findings from these studies swayed the decision of quite a few
menopausal women that were considering or currently undergoing HRT to avoid or discontinue treatment.
Despite this, there are still millions of middle-aged women in the U.S. who are presently undergoing
hormone therapy in an effort to relieve severe menopausal symptoms, aid in limiting osteoporosis and
reduce the risk of colon cancer (Ness et al., 2005). Most recently, some research has indicated an
additional benefit of certain types of hormone therapy— the preservation of the auditory system. Several
HRT studies involving the central nervous system have found that estrogen (E) may have neuroprotective properties that could possibly combat age-related hearing loss (ARHL). Similar studies have
also found that dwindling estrogen levels, due to age, can lead to declines in auditory function (Caras,
2013; Hederstierna et al., 2010). More specifically, Coleman and colleagues (1994) , for example, found
that Long-Evans rats had longer latency values compared to their counterparts treated with pramine, a
conjugated estrogen. Both groups of rats were ovariectomized, a procedure where both of the ovaries are
removed. Clinically, Kilicdag et al. (2004) found that for frequencies ranging from 0.25 to 16 kHz postmenopausal women consistently had higher mean hearing thresholds than women, similar in age,
undergoing estrogen therapy. Contrarily, combination HRT, estrogen and progesterone (E+P), has been
found to have a negative impact on the auditory system. Price et al. (2009) observed notably smaller
otoacoustic emission (DPOAE) amplitude values and higher auditory brainstem response (ABR)
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thresholds in peri-menopausal CBA/CaJ mice treated with E+P within 2 months of starting treatments,
exemplifying how influential the hormones can be regarding auditory system processing.
Although most studies have focused on the effect of HRT during treatment, no studies have
specifically evaluated hearing after hormone therapy has ended. Researchers have yet to fully understand
the health benefits and risks of discontinuing hormone therapy. Are the effects of HRT only seen when
while undergoing treatment? Or are the effects of hormone therapy reversible? Taking into consideration
the millions of women that have discontinued treatment due to the controversial findings from the WHI
and HERs studies, the answers to these questions prove to be relevant to a wide population of women. In
light of this, the following study was designed to evaluate the hearing of female CBA/CaJ middle-aged
mice undergoing HRT for a period of 6 months and after discontinuing treatment for 1 month. Auditory
Brainstem Responses (ABRs), ABR gap-in-noise (GIN), and Distortion Product Otoacoustic Emissions
(DPOAEs) were electrophysiological techniques used to record and analyze the responses of the inner ear
and brainwave activity, including auditory temporal processing. Meanwhile, anatomical and molecular
biological experiments (i.e., RT-PCR) were performed to assess the impact and biological mechanisms of
female sex hormones on the auditory system. The overall findings from my multidisciplinary doctoral
studies may help us understand how HRT affects the auditory system as well as its possible lingering side
effects after long-term use.

Background
Estrogen (E) and progesterone (P) are steroid hormones that play a vital role in the reproductive
system. E, which is predominantly synthesized in the ovaries, mediates the development and promotes
the growth of sexual characteristics of female humans and animals. Meanwhile, P is responsible for the
thickness of the uterus lining, which provides support for fertilized eggs during pregnancy. It should be
noted that P is produced in a structure, attached to the ovaries, known as the corpus luteum. Both
hormones fluctuate during the two phases of the ovarian cycle identified as the follicular and luteal phases
(Figure 1). During each of these phases, E and P activate other hormones such as the luteinizing hormone
!
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(LH), the follicular stimulating hormone (FSH) and vasopressin, all of which have an influence on the
female’s transition from being non-pregnant to completing parturition. More recently, scientists have
recognized the expression of estrogen receptors (ERs) and progesterone receptors (PRs) throughout
various parts of the body, including the brain and cochlea. Thus, indicating that E and P may have effects
on other biological systems in the body, in addition to the reproductive system. To date, ERs and PRs
have been known to participate in cell functions regarding the preservation of skeletal muscle, bone
formation, balancing electrolytes in cochlear fluids and influencing auditory transmission (Al-Mana et al.,
2008; Lee & Marcus, 2001; Olivieri et al., 2014; Ronkainen et al., 2009). For the purpose of this report,
the effects that E and P have on the auditory system will be emphasized and explored in novel ways.
Examination of the relevant research literature indicates that scientists have come to the
realization that there is a gender gap in hearing function in humans. Many studies have shown that at
younger ages, females have better hearing, i.e., higher amplitudes and lower latencies for ABR testing
than their male counterparts (Jerger & Hall, 1980; Rink, 2004; Wharton & Church, 1990). Similar
findings have also been observed in studies using DPOAE auditory tests; females typically displayed
lower DP thresholds and higher DP amplitude levels compared to male subjects (McFadden et al., 2009;
Torre et al., 2013). However, with age, female hearing levels start to decline significantly and become
similar to the males at older ages. Theories that may explain this phenomenon include sex-dependent
sizes of the external acoustic meatus, skin thickness, head size and/or sex hormonal influences (Coleman
et al., 1994; Elkind-Hirsch et al., 1992). For example, E may play a key role in the more sensitive
auditory system of women, until they go through menopausal changes, with one of the major effects
being declining hormone levels, including E. Specifically, Coleman and colleagues (1994) were one on
the first groups to investigate this situation with female Long-Evans rats that were ovariectomized (OVX)
at 3 months of age. This study discovered that OVX animals treated with 10 and 100 µg/kg of E had
significantly shorter inter-peak latencies for ABR waves at 40 kHz compared to control and OVX-only
groups. Similar effects were shown for ABR latencies for peak 1 (P1), peak 2 (P2) and peak 3 (P3) at 40
kHz. These results suggest (1) E can improve auditory system functioning and (2) E treatment starts to
!

3

plateau at 500 µg/kg. The fact that auditory function plateau’s at this dosage (500 µg/kg) suggests that
there is an optimal dosage for hormone treatment, which will prove to be useful in later studies. Another
pioneering study evaluated the ABR amplitudes and latencies between young and old human females and
compared their differences with young and old males (Wharton & Church, 1990). The participants
ranged in ages from 19 to 25 and 50 to 70 years old for the young and old groups, respectively. This
study found that for peak 5 (P5, generated in the auditory midbrain-inferior colliculus region) at 80 dB
nHL young adult females not only had higher amplitude values than young adult males but there was
more of a significant difference between the young and old female amplitudes than there was among the
males. For instance, the P5 group means were 0.66 and 0.50 µV for young and old females, respectively,
a 0.16 µV difference with age. Contrarily, there was only a 0.01 µV difference between the young and
old males; with their group means declining from 0.34 to 0.33 µV with age. The investigators concluded
that ABR amplitudes and latencies are a function of age and gender. Additionally, it can be implied that
declines in E during menopause negatively affected auditory processing since the old females were of
postmenopausal ages.
While the previously mentioned studies have examined hormonal changes that occur with age or
due to surgical removal of ovaries, there are other studies that present notable findings regarding changes
in E levels due to other biological occurrences, such as disease, or during the ovarian-driven menstrual
cycle. For example, one of the main symptoms of Turner syndrome, a genetically determined disease, is
ovarian dysgenesis, which severely decreases E levels potentially leading to ear and hearing problems
(Hultcrantz et al., 2006). Past clinical studies have found that Turner syndrome patients tend to have a
dip in their hearing thresholds for middle frequencies, more specifically at 1.5 to 2 kHz, for ABR
thresholds compared to healthy, normal hearing subjects (Hultcrantz & Sylvén, 1997; Stenberg et al.,
1999). The dip is generated from a ~10 dB threshold increase in these patients at these specified
frequencies. Another example of a disease that has an impact on the auditory system is Meniere’s
disease, which causes fluctuating hearing loss, tinnitus and vertigo. Meniere’s disease is more common
in women than men and often becomes more problematic during a woman’s menopausal phase
!
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(Paparella, 1991). Thus, suggesting that the disease may be exacerbated from declining or fluctuating E
hormone levels. Likewise, scientists have also assessed changes in hearing sensitivity during the ovarian
cycle since E levels fluctuate during this time. Different papers have reported controversial findings due
to the variability of the ovarian cycle in women (Al-Mana et al., 2008; Fehring et al., 2006). For
example, researchers have had difficulty accurately measuring E levels during the different phases of the
ovarian cycle. For instance, Table 1 shows E and P levels, taken from the serum of study participants,
during the follicular and luteal phases (Al-Mana et al., 2010). In Table 1, notice that E levels are
particularly high during the late follicular and early luteal phases. These hormone level changes coincide
with hearing sensitivity fluctuations as the study found a positive correlation between E and ABR
waveforms. Similarly, Caruso et al. (2003) and Serra et al. (2003) both found that higher levels of E,
during the follicular stages, generated shorter ABR latencies. However, other studies have reported
conflicting findings, such as no significant changes in ABR latencies during the ovarian cycle (ElkindHirsch et al., 1992; Fagan & Church, 1986). The theory as to whether hearing sensitivity increases during
the menstrual cycle is still debatable.

Table 1. Estrogen and Progesterone levels during the ovarian cycle
Time of Cycle

Oestradiol
pmol/L
152 ± 14.6

Progesterone
pmol/L
---

Early Follicular Phase
cycle day 5-8
Late Follicular Phase
469 ± 68.7
--cycle day 10-14
Early Luteal Phase
413.7 ± 46.8
47.8 ± 5.73
cycle day 20-23
Late Luteal Phase
236.2 ± 36.4
23.4 ± 5.37
cycle day 25-28
Fluctuating hormone levels during each phase of the ovarian cycle for women ranging from 22 to 49
years of age. Adapted from “Alteration in auditory function during the ovarian cycle” by D. Al-Mana, B.
Ceranic, O. Djahanbakhch, and L.M. Luxon, 2010, Hearing Research, 268, p.117. Copyright 2010 by
Elsevier B.V. Adapted, no permission required.
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Overall, it can be agreed that E plays a role in auditory system processing— however, what
different roles it plays are yet to be fully determined. Additionally, other studies have shown that P may
also influence the auditory system, since hearing sensitivity has been shown to increase coincident with
higher E and P levels (Al-Mana et al., 2010; Caruso et al., 2003; Serra et al., 2003). So far, researchers
have found that receptors for E and P, which mediate cell signaling throughout various parts of the body,
are located in both the brain and the cochlea. Estrogen receptors (ERs) consist of two subtypes ERα and
ERβ, with the latter more linked to neuro-protection in the central nervous system (CNS) (Charitidi et al.,
2010; Meltser et al., 2008; Turgeon et al., 2004; Wang et al., 2001). Specifically, Meltser and colleagues
observed that when mice, with normal expression levels of ERβs, were exposed to acoustic trauma, the
levels of the receptor’s agonist 2,3 bis (4-hydroxyphenyl)-propionitrile (DPN) increased, which led to an
upsurge of brain derived neurotrophic factor (BDNF). BDNF is a neuroprotective peptide that mediates
synaptic transmission and neural plasticity. The study concluded that a relationship exists between ERβ
and BDNF in the auditory system, which could be an explanation for some of E’s neuro-protective
properties. Similar to E, PRs have two isoforms, PR-A and PR-B, which are both localized in the CNS
(Brinton et al., 2008; O'Connell et al., 2011). Prior studies have suggested that both PRs interact with the
auditory system indirectly via gamma-aminobutyric acid (GABA) (Follesa et al., 2001).

For now,

scientists have determined that P may serve as an inhibitor to counteract the excitatory effects of E in the
auditory system (Katzenellenbogen, 2000). The full effects of P on acoustic function are still quite
understudied. Optimistically, the experiments of the present investigation will shed light on key roles P
may have in the central and peripheral auditory systems.
In addition to reproductive hormones, the insulin growth factor-1 (IGF-1) pathway has also been
linked to auditory system functionality over the lifespan. For example, previous studies have reported
that IGF-1 plays an important role in the formation of the cochlea during early developmental stages
(Camarero et al., 2001). During this time, IGF-1 levels peak throughout the body; however, with age, the
levels gradually decline, with these declines possibly linked to age-related susceptibilities to diseases
including various types of dementia (i.e., Alzheimer’s disease) and possibly presbycusis. Consistent with
!
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this, Staecker and colleagues (1998) have suggested that IGF-1 is essential for the maintenance and
possibly the survival of supporting cells and hair cells, two key functional components in the cochlea.
Therefore, lack of IGF-1 in the auditory system can be related to sensori-neural hearing loss (SNHL). For
instance, Camarero et al. (2001) found that in IGF-1 knockout (KO) mice loss of spiral ganglion neurons
was observed in only 3 weeks; meanwhile, degeneration of the stria vascularis (SV) occurred at 3 months.
Similarly, Iwai et al. (2001) observed reduced hair cell loss in rats treated with recombinant human (rh)
IGF-1, 3 days prior to noise exposure compared to rats that didn’t receive the treatment. The rhIGF-1
treated rats also had lower threshold shifts at 16 and 32 kHz compared to their untreated counterparts after
120 dB SPL noise exposure for 2 hours. Additionally, histological experiments showed that treated
animals were more likely to have outer hair cells (OHCs) intact relative to the control group. Researchers
have found that not only do declining IGF-1 levels cause increased susceptibility of hearing loss, but
mutations in the IGF-1 gene due to disorders/diseases can affect auditory function as well. For example,
Walenkamp and colleagues (2005) found that patients with severe intrauterine and postnatal growth
retardation, related to mutations in the IGF-1 gene, had acute bilateral hearing loss. Likewise, Attias et al.
(2012) observed considerably high ABR thresholds in patients with Laron’s syndrome, which is a
condition that causes IGF-1 deficiency. These reports suggest that IGF-1 contains preservation properties
that could attenuate hearing loss over time.
Another component that will be evaluated in this study is one of the forkhead transcription factors
(FoxOs)--- FoxO3. In mammals, there are 4 different types of FoxOs. However, FoxO3 will be the focus
of the study due to the fact that it has been linked to several cochlear structures, including the spiral
ganglion neurons (SGNs), inner hair cells (IHCs), and myelinating glia.

Specifically, Gilels and

colleagues (2013) have recently found that FoxO3 is an important factor in the synaptic function in IHCs.
After only 4 months, FoxO3 knockout (KO) mice had significantly higher ABR thresholds than control
wild type animals. Although the IHCs structure between the 2 groups were similar, FoxO3 KO mice had
less and/or deformed neurons within the cochlea. This was believed to be the cause of degeneration of
IHC/auditory nerve fiber ribbon synapses in the cochlea, which in turn can delay or prevent the cochlea
!
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and brain from interacting with one another for normal hearing. The study also found that distortionproduct otoacoustic emissions (DPOAEs) were intact, indicating normal functioning of the cochlear OHC
system. There are very few research studies that have specifically investigated FoxO3’s impact on
auditory function.

A goal of the present study was to investigate links between hormone-related

deterioration, the cochlea, and the brain to the FoxO3 gene. Hopefully, it will provide necessary insights
to the biological mechanism regarding what is occurring when hormones, or a lack there of, influence the
aging auditory system at different functional levels.
Collectively, previous investigations have reported that IGF-1 and FoxO3 play an important role
in mediating anti-apoptotic responses via the phosphoinositide 3-kinase (PI3K) pathway (Varela-Nieto et
al., 2004, 2007; Tang, 2006). This could explain IGF-1’s and FoxO3’s potential protective properties in
the cochlea. This pathway is activated when the IGF-1 receptor (IGF-1r), a type of tyrosine kinase
receptor (RTK), binds to the IGF-1 ligand in order to recruit PI3-K to the plasma membrane of the cell. A
subunit attached to PI3K, p110, then becomes phosphorylated and triggers the conversion of
phosphatidylinositol 3,4 triphosphate (PIP2) to phosphatidylinositol 3,4,5 triphosphate (PIP3). High
levels of PIP3 promote AKT sequestration in the cytosol of the cell. The AKT structure then becomes
activated after the protein is phosphorylated at its serine/threonine sites by the following substrates:
phosphoinositide-dependent kinase-1 (PDK1) and the mTOR complex 2 (mTORc2). Once AKT is
phosphorylated multiple cell functions can occur such as angiogenesis, protein translation, cell
proliferation, cell survival and metabolism (Refer to Figure 1). A focal purpose of the present study is to
investigate key properties of the PI3K/AKT pathway and its roles in cochlear cell survival and antiapoptotic responses, which can be regulated by the FoxO transcription factors, since FoxOs have been
shown to play an active role in the survival of cells through the activation of AKT.

FoxOs inhibit the

DNA transcription of pro-apoptotic genes such as BIM, Fas ligand, TRIAL and TRADD.
permutations promote cell survival as well as growth in various physiological systems of the body.
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These

Figure 1. Model of the intracellular PI3K/AKT pathway. IGF-1 binds to tyrosine kinase receptors
(RTK), IGF-1r to recruit PI3K to the plasma membrane. Subunit p110 undergoes a conformational
change, which triggers the conversion of PIP2 to PIP3. The increase in PIP3 leads to the accumulation of
AKT in the cytosol of the cell. AKT then transforms to an activated state when AKT residues, T308 and
S473, are phosphorylated by PDK1 and mTORc, respectively. Once AKT becomes activated, multiple
cellular functions can occur via the phosphorylation of various substrate proteins. The 5 functions
mediated by the PI3K pathway are angiogenesis, translation, cell proliferation, cell survival and
metabolism. AKT becomes inactive when molecules PP2A and PHLLPs de-phosphorylate residues T308
and S473. Deactivated AKT is then returned to the cytosol of the cell for storage. Inhibitors: PTEN, a
liquid phosphate, limits AKT activation by converting PIP3 to PIP2. When less PIP3 is available in the
cell, it decreases the chances of AKT becoming activated. PHLDA3, a pH domain only protein, competes
for any PIP3 that is obtainable in the cell. Thus, limiting the amount of activated AKT. TRB3 and
CTMP prevent the phosphorylation of residues T308 and S473. Adapted from ”Phosphoinositide 3Kinase in Health and Disease” by C. Rommel et al., 2010 , Current Topics in Microbiology and
Immunology, 347, p.109. Copyright 2010 by Springer-Verlag Berlin Heidelberg. Adapted with
permission.
All in all, the following experiments will help to shed light on what takes place in the auditory
system during and after hormone therapy.

Phase I experiments include administering hormones to

animals over a period of 6 months followed by a 1 month wash out period to evaluate the long-term as
well as the lingering side effects of HRT.

!

During this time, the animals will undergo thorough
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examination of hearing capabilities.

Phase II of the study will involve anatomical and molecular

experiments to observe how hormones influence physiological mechanisms, such as the IGF-1 pathway,
in the auditory system. More specifically, the PI3K/AKT pathway’s two key components, IGF-1r and
FoxO3, will be assessed in cochlear cells, both in vitro in a stria vascularis (SV) cell line, and in vivo in
cochlear tissue samples from aging mice. Evaluating the effects that E and P have on the up/down
regulation of key genes will help to understand the relationships, if any, between the hormones and the
IGF-1 cell cycle pathway. This project will help researchers, physicians as well HRT patients gain better
insight to the protective properties of E, or the deleterious effects of P, and how the IGF-1 pathway may
play a role in preservation of auditory system functionality.

Purpose for the Present Study
There are currently various hormonal therapy drugs on the market, such as Premphase and
Yasmin that many women of different ages are taking, under the guidance of their doctors. Some women
take HRT for relief of menopausal symptoms; meanwhile, younger women undergo hormone therapy for
birth control purposes. While most of these drugs have proven to be beneficial, the lingering side effects
that are produced by the long-term use of these drugs needs to be further evaluated. The purpose of the
following investigation was to examine the overall effects and aftermath of HRT on the central and
peripheral auditory systems in aging mice. Thus far, it is known that E generally has a positive impact on
the auditory system by improving ABR thresholds; meanwhile, E+P has adverse effects on hearing by
causing declines in temporal processing, spatial processing and speech recognition, as well as increasing
ABR thresholds in animal models and audiometric thresholds in aging women. The present study plans
to explore the specific roles of E and P in more detail, and to determine whether or not these effects
remain after HRT is discontinued.
The present investigation will be broken up into 2 main phases. Phase 1 entails the evaluation of
sex hormone effects on the auditory system via tests such as distortion product otoacoustic emissions
(DPOAE), auditory brainstem response (ABR) and ABR gap-in-noise (GIN). HRT will be administered
!
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long term and then discontinued for a period of 1 month. Phase 2 involves anatomical and molecular
biological experiments that will help to explain the results of the electrophysiological data from Phase 1.
The impact of E and P on the IGF-1 pathway will be studied in further detail. As mentioned above, the
IGF-1 pathway is involved in cell survival through the activation of transcription factors such FoxO3.
Experiments will be performed to see if E and/or P activate the cell survival mechanism in sensory cells
in the auditory system. For the in-vitro experiments, the most useful SV cell line available will be
utilized.
Novel, innovative aspects of the present study include (1) treating animals with hormone therapy
over a period of 6 months (long-term), (2) administering P alone to evaluate its sole effect on auditory
system processing and (3) examining the relationships between the IGF-1 pathway and the protective
properties of E. Most auditory-hormone based studies have looked at the effects of treatment from only a
week to over a course 4 months (Coleman et al., 1994; Price et al., 2009). Very few have looked into
treating animals over long periods of time, such as 6 months, and including a “recovery” period.
Looking into treatment for such a long period of time will allow the study to provide more realistic and
accurate findings for the changes that occur over time with HRT; since essentially, most women that
undergo hormone therapy do so for years. Additionally, many studies have suggested that P is the
negative component in the E+P duo, since combination treatment has such negative effects. The specific
actions of P on the auditory system, i.e., benefits and/or risks of administering P alone, are still unknown.
Lastly, the IGF-1 pathway has also been linked to reduction in inflammation and oxidative stress; thus, it
may play a critical role in the aging process (Sukhanov et al., 2007). E has been implicated, from
theoretical, scientific and clinical perspectives, to improve age-related hearing loss (ARHL) through its
protective and trophic properties. However, its specific cellular and molecular mechanisms properties are
still not fully understood. The following experimental plan considers the IGF-1 pathway as a possible
candidate to achieve hearing improvement through the administration of sex steroid hormone treatments.!!
Optimistically, the findings from this study will lead to a better understanding of how hormones affect the
aging auditory system as well as the protective properties of E (and potentially P).!
!
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Hypothesis
Phase I Experiments
Previous studies have suggested that progesterone (P) and combination treatment (E+P) are
detrimental to the auditory system (Guimaraes et al., 2006; Price et al., 2009). Therefore, I predict that P
and E+P treated animals will show signs of improvement in ABR thresholds and ABR GIN amplitude
levels only after treatment is discontinued, during the washout/recovery period. However, P and E+P
treatments will cause accelerated signs of ARHL during the 6-month course of treatment. On the other
hand, previous studies have reported that E improves auditory function over time. I hypothesize that
animals treated with E will probably have increased thresholds once treatment has ended. Overall,
discontinuing treatment may have various effects on hearing function; depending on which hormone(s)
the animals are being treated with. For example, if a hormone shows positive results during HRT,
hearing thresholds may increase over period of time once treatment has ended.
Phase II Experiments
Studies have shown that IGF-1 pathway elements expression are at their highest during
embryonic and early postnatal development. Contrarily, when ontogenetic development is complete,
IGF-1 levels gradually decline with age. These neurotrophic factors possibly only become prominent
again during biological stress events, such as apoptosis and inflammation, in which cells need to be
protected or repaired. I hypothesize that there will be a significant difference between the IGF-1 and
FoxO3 expression levels between E and E+P treated animals. E+P has been shown to be detrimental to
the auditory system; therefore, the expression levels for IGF-1 and FoxO3, both of which have been
linked to cell survival, will be lower in these animals compared to mice treated with E and P, individually.
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CHAPTER TWO
INITIAL EXPERIMENTS: PHYSIOLOGICAL BIOMARKER FOR AGE-RELATED HEARING
LOSS
Before any of the HRT experiments took place, initial experiments were performed on middle
aged and young adult mice to evaluate the initial signs of temporal processing deficits, which are
commonly associated with age-related hearing loss (ARHL). A novel paradigm known as auditory
brainstem responses (ABR) gap-in-noise (GIN) was used to test auditory temporal processing. The ABR
GIN techniques use the same basic sounds that elicit ABRs to measure the temporal processing abilities
of subjects at various sound temporal gap intervals. These results allowed our team to gain better insights
into the beginning stages of the aging process in the auditory system. These findings also helped in
moving forward with the HRT project experimental design. For instance, it was determined that the
CBA/CaJ strain starts to display middle age temporal processing changes around 12 to 15 months. The
current Chapter 2 was based closely upon and adapted from the text and figures from my first peerreviewed article (Williamson et al., 2015). 1

Abstract
The auditory function of the CBA/CaJ mouse strain is normal during the early phases of life and
gradually declines over its lifespan, much like human age-related hearing loss (ARHL), but within the
timeframe of mouse life cycle “time frame”. This pattern of ARHL is relatively similar to most humans:
difficult to clinically diagnose at its onset, and currently not treatable medically. To address the challenge
of early diagnosis, CBA mice were used for the present study to analyze the beginning stages and

!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1!The following chapter was published in Cell and Tissue Research (Williamson et al. (2015) Auditory
brainstem gap responses start to decline in mice in middle aged: a physiological biomarker for age-related
hearing loss. Cell Tissue Res. 361(1), 359-369). Permission is included in Appendix C.
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functional onset biomarkers of ARHL. The results from Auditory Brainstem Response (ABR) audiogram
and Gap-in-noise (GIN) ABR tests were compared for two groups of mice of different ages, young adult
and middle age.

ABR peak components from the middle age group displayed minor changes in

audibility; but had a significantly higher prolonged peak latency and decreased peak amplitude in
response to temporal gaps in comparison to the young adult group. The results for the younger subjects
revealed gap thresholds and recovery rates that were comparable to previous studies of auditory neural
gap coding. Our findings suggest that age-linked degeneration of the peripheral and brainstem auditory
system is already beginning in middle age, allowing for the possibility of preventative biomedical or
hearing protection measures to be implemented as a possibility for attenuating further damage to the
auditory system due to ARHL.

Introduction
Age-related hearing loss (ARHL) is one of the most prevalent neurodegenerative disorders and
communication problems of our aging population and belongs to the highest prevalence category of
chronic medical conditions of the aged, together with arthritis and cardiovascular diseases (Cruickshanks
et al., 1998; Gopinath et al., 2009). In previous investigations of ARHL (clinically termed presbycusis),
the gap detection paradigm was employed to measure temporal processing in both animals and human
subjects. Auditory temporal processing refers to the ability of auditory neurons to code stimulus temporal
features with high temporal resolution, so that this temporal information can be processed accurately in
the parts of the brain used for hearing and the perception of complex sound features. Traditionally,
temporal processing deficiencies within the auditory system have been attributed to deficits within the
inner ear, commonly defined as peripheral sensorineural hearing loss (SNHL) (Buus & Florentine, 1985;
Fitzgibbons & Wightman, 1982; Florentine & Buus, 1984; Tyler et al., 1982). For instance, Florentine
and Buus (1984) found that subjects with SNHL display poorer temporal gap detection even at high
sound levels when compared with listeners with normal hearing. Analogously, Fitzgibbons and
Wightman (1982) assessed gap detection thresholds for various octave-band conditions and found that
!
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hearing-impaired listeners consistently have higher thresholds than normal- hearing listeners at equivalent
sound pressure levels (SPL). The difference has been attributed to “processing distortions imposed by
cochlear damage” (Fitzgibbons & Wightman, 1982).
Prevailing evidence links age-related difficulties with temporal coding to neural deficits in the
central auditory system (CAS), in addition to peripheral processing problems. For example, Walton and
colleagues found significant age- changes in behavioral temporal responses and single-neuron temporal
processing in the brainstem in aging CBA/CaJ mice with relatively good peripheral hearing sensitivity
(Frisina, 2001; Walton et al., 1997; Walton et al., 1998). Additionally, Moore et al. (1992) reported
differences between young and old subjects for suprathreshold gap detection measured from 400 to 2000
Hz. Similarly, Lutman (1991) observed age-related differences in the dynamic frequency resolution
abilities of subjects ranging from 17 to 80 years of age. He et al. (1999) reported that aged subjects have
considerably higher gap detection thresholds than young adults, especially when the gap is presented
randomly and placed at 5 % or 95 % time points in the overall noise stimulus. Likewise, Schneider and
Hamastra (1999) presented findings indicating that older adults have impaired temporal processing
abilities in comparison with their younger counterparts, notably for shorter gap durations utilizing two 2
kHz tone pips.
Additional animal model experiments have also shed light on the conflicting theories concerning
peripheral vs. central age-related effects on auditory temporal processing (Gleich & Strutz, 2011; Poth et
al., 2001; Simon et al., 2004; Walton et al., 2008a). For example, Walton et al. (2008) reported that 6- to
10-month-old C57 mice begin to show signs of high frequency SNHL but also have temporal processing
abilities parallel to those of 6- to 10-month-old CBA mice with no significant peripheral hearing loss
(Walton et al., 1998). Moreover, Gleich and Strutz (2011) described gap thresholds that are significantly
higher in aged gerbils than in young adult gerbils before and after the administration of gabapentin
treatment. More of a difference can be seen between the groups when the sound intensity is decreased
from 30 to 15 dB SPL (Gleich and Strutz 2011). Overall, these results indicate that the aging central
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auditory system is a major contributor to auditory temporal processing deficiencies characteristic of
ARHL.
Hence, although age changes in auditory temporal processing are becoming better understood,
certain aspects remain unclear. For instance, at what age or stage in life does temporal processing of
sound features start noticeably to decline? In most previous studies, comparisons have only been made
between young adult and old subjects. The ages at which temporal processing declines start to take place
remain elusive. In light of this, the present study aims to compare the temporal processing abilities of
young adult and middle age CBA/CaJ mice by using the auditory brainstem response (ABR) Gap-in-noise
(GIN) paradigm. ABR GIN is a novel approach for measuring temporal processing in aging animals,
whereas most previous studies used single- or multi-unit gap detection paradigms or behavioral
methodologies (Walton et al., 1997). The ABR GIN paradigm provides information concerning the ability
of the auditory periphery and brainstem to process temporal gaps in ongoing sound by measuring various
waveform components of the ABR. For the present investigation, Peak I (P1) and Peak IV (P4) were
assessed in order to determine the minimum gap thresholds (MGT), the peak latency, the peak amplitude
and the recovery function of P1 and P4 for mice of various ages. The results indicate that prominent signs
of ARHL-linked temporal coding deficits, with higher response latency values and lower amplitude
levels, strikingly emerge in middle age.

Methods and Materials
Subjects
Sixteen CBA/CaJ mice, bred in-house, were classified into two groups, young adult (Y, n=8, 3 to
4 months old) and middle age (MA, n=8, 15 to 18 months old). With the same procedures as in our
previous reports, distortion product otoacoustic emissions (DPOAEs) were used to characterize the
functionality of the outer hair cell system (Borkholder et al., 2014; Frisina et al., 2011; Zhu et al., 2007).
No medication or other potentially ototoxic procedure was administered. The subjects were anesthetized
by an intraperitoneal injection of a ketamine/xylazine mixture (120 and 10 kg/mg body weight) prior to
!
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all experimental sessions. All of the animal protocols were approved by the University of South Florida
Institutional Animal Care and Use Committee (IACUC).
Stimulus Presentation and Physiology Recordings
Acoustic stimuli were synthesized digitally by using the System III Tucker-Davis Technology
(TDT, Alachua, Fla., USA) signal-processing platform. The stimuli were then attenuated and filtered
(low-pass cutoff at 5 kHz). Stimulus sounds were presented through an electrostatic speaker (TDT EC1)
connected to the external ear canal by 4 cm tubes, namely via a calibrated closed system. A 0.6-cm B&K
micro- phone (Type 4938, Bruel & Kjaer, Naerum, Denmark) attached to a 0.1 cm3 coupler was used to
calibrate the TDT system daily. The mice were placed on a heating pad inside a soundproof booth. Three
sub-cutaneous needle electrodes were inserted at the vertex (non-inverted) and in the mastoid area muscle
of the ipsilateral (testing) side (inverted), with a ground electrode being inserted into the muscle posterior
to the contralateral pinna to record the ABR responses of each mouse. These electrodes were connected to
a bioamp headstage (HS4 Fiber Optic, TDT). For ABR threshold experiments, the subjects were
presented with tonal stimuli in the frequency range of 3 to 48 kHz at various sound levels (5 dB intensity
steps) to determine thresholds. A wide band noise (WBN) stimulus, having a bandwidth from 0 to 48
kHz, was also used. The duration for each ABR stimulus was 5 ms, presented at a repetition rate of 21/s.
For ABR GIN, a silent gap was inserted in the center of two WBN bursts, NB1 and NB2, at 80 dB SPL,
each with a repetition rate of 21/s, duration of 25 ms and rise-fall times of 0.5 ms. Each averaged response
was obtained from 100 stimulus presentations and then duplicated with another 100 repetitions. Gap
durations were 0, 1, 2, 4, 8, 16, 32 and 64 ms. Responses were recorded by using BioSig (TDT) and
duplicated for each gap duration tested, an example of which is given in Figure 2. The time span for each
ABR GIN audiogram response window was 150 ms.
Data Analysis: ABR Thresholds and ABR GIN
For ABR testing, thresholds were determined at each frequency by various experimenters who
tested both age groups, blinded to the animal’s age. The threshold was defined as the lowest sound level
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at which a distinct ABR wave could be identified. ABR recordings for all nine tonal stimuli (3– 48 kHz),
together with WBN stimuli, were evaluated and compared for the two different subject groups, namely
young adult and middle age.
ABR GIN analysis consisted in first identifying the smallest gap duration with a response to the
second noise burst (NB2), i.e., MGT (Buus and Florentine 1985; Nelson and Thomas 1997). Responses to
the first noise burst (NB1) consist in a series of 4–5 ABR peak waves. Meanwhile, an ABR peak response
for NB2 was elicited depending on the gap duration being presented; at shorter gap durations, either small
or no ABR peaks would be generated and larger gap durations produced clearer ABR peak waves. The
time and magnitude of these wave peaks were used to formulate latency and amplitude statistics. Latency
values were measured by subtracting the time of the P1 NB2 response from the ending time of the gap
duration (see Figure 2). This value signified the time at which the onset response to the termination of the
gap occurred or the delayed response to NB2. Latency shift values were calculated by subtracting the time
at which the NB1 response occurred from the time that the NB2 response took place. The latency shift
indicates the speed of recovery of the system from NB1. Furthermore, the wave amplitudes were obtained
by subtracting the trough from the peak levels for P1 and P4 (Figure 2). Control amplitude values for P1
and P4 were identified for each mouse by using NB1. A comparison was then made with the NB2
amplitude values. Specifically, recovery ratio values were determined by dividing the NB2 amplitude by
the NB1 amplitude for both P1 and P4.
A two-way analysis of variance (ANOVA) was used to analyze statistically the amplitude levels,
recovery ratios and latency values for the young adult and middle age groups. Bonferonni’s multiple
comparisons post-hoc tests (MCT) were used to assess pairwise comparisons between conditions when
the main effects of the ANOVA were statistically significant. All error bars in the figures are standard
errors of the mean (SEM).
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Results
Hearing Sensitivity in Middle Age: ABR Thresholds
Individual ABR audiograms presented in Figure 3a show that, although most of the MA group
has higher thresholds than the Y group, some of the thresholds do indeed overlap for the two age groups.
This indicates that ARHL is just beginning in this strain of mice at about 15 months. A clearer depiction
of the differences between the two groups can be seen in the aver- aged threshold values. According to
Figure 3b, the MA group has a threshold that is approximately 10 dB higher than that of the Y group
across the stimulus frequency range used. This analysis confirmed that modest differences were present in
the hearing levels between the two groups of mice, namely Y and MA.

Figure 2. Representative ABR waveform from a young adult mouse elicited by the Gap-in-noise (GIN)
stimulus. It should be noted that the following waveform is the averaged response for a gap duration of 8
ms that was replicated twice. The amplitude for each ABR wave peak was measured by using the peak-totrough technique. Meanwhile, the latency was calculated by subtracting the time of the ABR peak
response to the stimulus from the starting time of NB2.
MGTs were determined as the lowest gap duration at which a response appeared for NB2, as
presented in Figure 4. All eight Y mice had an NB2 response for gaps of 2 ms and greater. However,
only about half (5 out of 8) of the mice in the MA group generated a response for NB2 at 2-ms gaps,
whereas all eight MA mice had an NB2 response for gaps of 4 ms and greater. Thus, as predicted from
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previous studies showing central auditory temporal coding deficits with age, the MA group had a higher
mean MGT than that of Y. These findings were confirmed by computing the ABR GIN grand average at
2, 4 and 8 ms for both groups. As seen in Figure 5, the response of MA mice at 4 and 8 ms could be
clearly depicted; however, at 2 ms, the NB2 response was not present. The Y group, on the other hand,
elicited a response that was clearly distinct for all three of the shortest gap durations.

a

b

Figure 3. ABR threshold comparison between Y and MA mice. Wide band noise (WBN) thresholds were
also determined. (a) Thresholds for each mouse in the two groups of young (Y) and middle age (MA)
show that, although the majority of the MA values are higher than those of Y, some of the thresholds still
overlap between the two groups. (b) Averaged threshold values clearly show that the Y group has
thresholds that are approximately 10 dB lower than those of the MA group, especially at 12, 16, 20 and
24 kHz. Statistical tests: ANOVA followed by Bonferroni; *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001.
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Figure 4. Minimum gap thresholds (MGT) comparison between Y and MA mice. The subject response
shows the percentage of mice that elicited an NB2 response. MA displayed percentage values lower than
Y at 2 ms; however, as the gap duration increased, more mice responded to the stimulus. By 4 ms, all of
the MA mice responded to the NB2 stimulus. The Y group consistently showed a 100 % group response
for all of the gap durations.

a

b

c

Figure 5. Representative waveform analysis that was used to determine the MGT between the Y and MA
groups. MGT is defined as the lowest gap duration at which an NB2 response occurs. (a) At 2 ms, the
MA group shows no NB2 response; however, the Y group clearly displays ABR waves. Therefore, the
MGT for group Y is 2 ms. (b) By 4 ms, the MA group starts to show signs of P1 waveform. As a result,
the MA group has an MGT of 4 ms. (c) At 8 ms, both groups also show P1 waveforms. However, the
peaks of the Y group are notably larger than those of the MA group. The line underneath each audiogram
indicates the time point at which the NB2 stimulus was given.
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Temporal Processing: ABR GIN Amplitudes
The average ABR GIN amplitude values for Peak I (P1) and Peak IV (P4) are displayed in Figure
6. A t-test analysis verified that the MA group had significantly lower amplitudes than the Y group for
both peaks (P1, t = 5.46, P < 0.0001; P4, t = 2.14, P = 0.041). Figure 6a shows that the control amplitude
levels for P1 were 6.17 mV for Y and 2.79 mV for MA. Meanwhile, P4 amplitudes were 2.72 mV and
1.39 mV for Y and MA, respectively. Notably, one common observation was that P1 amplitudes were
larger than P4 amplitudes for both groups.
The experimental amplitude levels of NB2 systematically increased as the gap durations
increased. As presented in Figure 6b, the amplitude levels for the MA group initially were 0.66 mV for 4
ms for P1 and gradually rose to 1.32 mV at 64 ms. Meanwhile, group Y had amplitude levels ranging
from 1.38 to 3.52 mV for 4- and 64-ms gap durations, respectively. Significant differences were observed
between the two groups for gap durations of 12, 16, 32 and 64 ms (Fage[1,70]= 136; P < 0.0001). A 3.39
mV difference was recorded between the Y and MA groups for P1 control values. Notably, P4 had
relatively smaller amplitude values than P1; however, a positive trend could still be seen (Figure 6c) as
the gap duration increased. Specifically at 4 ms, the amplitudes for the Y and MA groups were 1.06 mV
and 0.43 mV, respectively. By the time that the gap interval had increased to 64 ms, the values had
increased to 1.58 mV for Y and 0.81 for MA. The amplitude differences between the two groups
increased as the gap duration increased for P4. For instance, the smallest difference between Y and MA
for P4 took place at 4 ms (Bonferonni’s MCT, P=0.006); meanwhile, at 64 ms, a large difference was
observed in amplitude levels (Bonferonni’s MCT, P=0.0005).
Significant recovery ratio values could be seen in both groups of mice for P1 and P4. However,
even at longer gap durations, MA amplitude levels still did not reach those of Y but they became
increasingly similar to the control values seen in Figure 6a. P4 amplitude levels for MA seemed to
become more parallel to Y with time. Both groups also had values that were strikingly similar to the
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control amplitude levels at 64 ms. With longer gap durations than those used for this experiment, the
mice might have reached levels close to the control amplitudes in Figure 6a.

a

b

c

Figure 6. ABR GIN amplitude comparison between Y and MA for P1 and P4. Peak 1 (P1) and Peak 4
(P4) amplitude levels for both groups show that the Y group consistently had higher amplitude values
than MA for NB1 and NB2, respectively. (a) Control amplitude for NB1 for P1 and P4. (b) As the gap
duration increases, the amplitude atNB2 for P1 comes closer to its control value. Significant differences
can be seen between the Y and MA groups at 4, 8 and 16 ms. (c) Amplitude levels at NB2 for P4 are
much smaller than P1. P4 Amplitude values are notably higher for Y than MA at 4 ms. Statistical tests: a t
test; b, c ANOVA followed by Bonferroni; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

ABR GIN Recovery Percentages
Figure 7 displays the same positive relationship between gap durations and recovery percentages
to the trends seen for the amplitude levels in that they both showed positive trends. However, the recovery
percentages did not show the notable differences seen in the amplitude levels, when comparing Y and
MA. Figure 7a shows that the Y group had a recovery percentage analogous to that of MA for smaller gap
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durations; however, as the gap duration increased, a difference of approximately 10 % could be seen in
the recovery function (Fage[1,70]=8.96, P=0.0038). For instance, both Y and MA groups had a recovery
of approximately 25 % at 4 ms for P1. As gap durations increased to 64 ms, the recovery ratios improved
to 58 % for Y and 47 % for MA (Bonferroni MCT, P = 0.0339). On the contrary, Figure 7b shows that
the two groups of mice recovered at different rates before their values became similar for longer durations
for P4 (i.e., a significant difference can be seen at 8 ms but for the 64-ms gap, both groups have an NB2
response that is similar to NB1 at 56 %).
Response Latency
An inverse relationship can be seen in Figure 8 between the latency values and gap durations
(Fage[1,84]=17, P<0.0001). Initially, the Y and MA groups had control NB1 latency values of 2.56 ms
and 2.71 ms, respectively (not shown). In response to the NB2 stimulus, P1 latency increased to 2.79 ms
for Y and 2.93 ms for MA, for a gap interval of 4 ms. However, the latency decreased as the gap duration
became longer. As the gaps increased, the auditory neurons had more time to recover from NB1 and
could respond more efficiently to NB2. For example, group Y latency dropped by 0.17 ms, whereas MA
latency declined by 0.15 ms at 64 ms. The final latency values taken at 64 ms were somewhat congruent
to the control latencies, mentioned above, for both subject groups. Figure 8a shows that differences
between the groups increased as the gap durations became longer. Hence, the largest difference between
the Y and MA mice was observed at 64 ms. Notably, latency values for NB1 and NB2 were parallel between the Y and MA groups, with MA having consistently higher values. This indicates that auditory
temporal processing abilities have some common features for the two age groups; however, the initial
signs of ARHL are occurring significantly in middle age.
Latency shifts were also analyzed in this study.

As expected, the latency shift decreased

considerably as the gap duration increased. Figure 8b shows the MA group with a latency shift of 0.33
ms for the 4-ms gap. For the same gap interval, group Y had a slightly lower latency shift of 0.24 ms. As
the neurons had more time to recover from NB1, the latency shift gradually declined to about 0.09 ms for
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a

b

Figure 7. P1 and P4 recovery ratios for Y and MA groups. (a) Recovery ratios for Peak 1 (P1) were
analogous for the Y and MA groups at 4 ms. However, ratios for the Y group began to improve as gap
durations became longer. Significant differences can be seen between the groups at 16 and 64 ms. (b)
Conversely, recovery ratios for Peak 4 (P4) vary greatly at 4 ms. By 32 ms, the MA group starts to
recover almost as well as the Y group. The Y group displayed higher percentage values for wider GIN
durations for P1. For P4, higher Y percentages could be seen for smaller GIN durations. Statistical tests:
ANOVA followed by Bonferroni; *P<0.05.
groups Y and MA. The latency shift difference between the two groups for the 4-ms gap suggests that the
MA group still has the capability to respond to noise burst stimuli but not as accurately as that of the Y
mice. Figure 8b also shows the way that the latency shift for the MA group asymptotes for the two
longest gap durations. Specifically, the latency shift is 0.09 ms for the 32- and 64-ms gaps. Meanwhile,
the latency shift for the Y group continues to decrease for the longest gaps. No significant differences
between the Y and MA groups were seen at any of the gap durations. Similar to the latency response, the
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latency shift values for group MA were parallel to those for group Y (Figure 8b) but with the MA mice
being consistently higher for the absolute latencies (Figure 8a).

b

a

Figure 8. P1 NB2 latency values for Y and MA mice. (a) Plotted average latency values distinctly show
that the Y latency values are consistently shorter than those of the MA group. Moreover, significant
differences for latency can be seen at all gap durations between the two age groups. (b) Mean latency shift
values show that Y and MA groups vary slightly between, the two age groups. This age difference in
latency shift was not statistically significant. Statistical tests: ANOVA followed by Bonferroni; *P<0.05,
**P<0.01.
Discussion
In this study, we demonstrated that middle age mice start to show temporal processing deficits
characteristics of ARHL at 15 months of age; we focused on the ABR GIN response for P1 and P4, which
have been chosen because of their similarities to wave I and wave V ABR peaks in humans. Previous
studies of wave I and wave V suggest that they comprise a useful robust response in humans (Boettcher,
2002), with the peaks being generated from various parts of the cochlea and brainstem auditory system.
For instance, P1 (wave I for humans) is produced by the auditory nerve, whereas P4 (mice) and wave V
(human) are generated from the lateral lemniscus/inferior colliculus (IC) of the brainstem (Hashimoto,
1989; Hashimoto et al., 1981; Moller & Jannetta, 1982, 1983). With age, the degeneration of auditory
brainstem neural circuitry contributes to the reduction in ABR peak responses.

In the present

investigation, these age-related changes were observed by comparisons of the amplitude levels and
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latency values for the Y and MA groups. For instance, with reference to Figures 6 and 8, the Y group
consistently displays better gap processing relative to the MA group. Although the ABR peak amplitude
and latency values are significantly different, similarities can be seen in the shape of the NB2 recovery
functions for both age groups, as displayed in Figure 7. Thus, a major finding of this experiment is that
initial signs of neurophysiological changes that degrade auditory temporal processing can be detected by
ABR gap measures probably reflecting neuron and neuroglia loss, the decline in myelin sheaths and the
reduction in brainstem volume/weight, which start to occur in middle age (Khullar & Babbar, 2011),
together with the declines in auditory brainstem neuronal connectivity (Frisina & Walton, 2006).
Hearing Sensitivity: ABR Thresholds
Although an overlap occurs between individual ABR threshold functions (Figure 3a), a mean
difference of about 10 dB was found for the two subject groups in the present investigation (Figure 3b).
Hence, absolute sensitivity differences might ex- plain some of the temporal processing declines in
middle age. However, Buus and Florentine (1985) conducted a study in which they found that human
subjects with high-frequency hearing loss had MGTs similar to subjects with normal hearing at high
sound levels, such as those used in the present investigation (i.e., 80 dB SPL). Nelson and Thomas (1997)
used the same logic to interpret their findings while testing normal and hearing-impaired subjects who
were found to have similar MGTs at 3 ms. Similarly, Walton et al. (2008) com- pared neural MGTs from
IC neurons from hearing-impaired C57 mice with those of old CBA mice and found that the neural MGTs
were not significantly different from one another. Thus, although sound level probably exerts a minor
influence, aging and other factors play a more prominent role in explaining the temporal processing
deficits observed in the middle age mice of the present investigation (Figure 4).
Aging Effects on Temporal Processing: ABR GIN Amplitude Levels
For NB1, the MA control amplitude levels are reduced by nearly 50% of that of the Y group for
P1 and P4,as seen in Figure 6a. Likewise, the NB2 amplitude levels for MA are consistently lower than
those for the Y mice for both peaks (Figures 6b and 6c). As the gap durations increase, the differences
between the age groups recede. Similar results were seen when Boettcher et al. (1996) compared the
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temporal processing abilities of young adult and aged gerbils. P4 NB1 amplitudes for aged gerbils were
from 1.5 to 0.5 mV, whereas the young adults had greater amplitudes, from 3 to 1.5 mV (Boettcher et al.,
1996), much like the same two-fold variance that was seen in P4 on comparison of Y and MA mice in the
present investigation. As for NB2 amplitude levels, the differences between the age groups escalated
when the gap duration became longer for both P2 (the gerbil equivalent to P1) and P4 (Boettcher et al.,
1996). For instance, at a gap duration of 2 ms, both young and aged gerbils had amplitude levels that were
not significantly different from the noise floor at approximately 0.25 mV (Boettcher et al., 1996).
However, as the gap durations increased, the initial P1 and P4 values progressively improved to 3 mV for
the young adult gerbils and 1.5 mV for the old gerbils. Thus, Boettcher’s study demonstrated that, even
with longer gaps, aged gerbils still had significantly lower amplitude ABR waves than their young
counterparts. In the present investigation, we confirmed that these same differences can be seen as early
as middle age in CBA/CaJ mice, reinforcing the usefulness of the ABR GIN paradigm as a physiological
early diagnostic biomarker for ARHL temporal processing deficits.
Prior studies have attributed the age-linked reduction in amplitude levels to reduced temporal
synchronization in auditory neurons, a decrease in the number of neurons that elicit a response to the
stimulus and/or a reduction in the endocochlear potential (Boettcher, 2002; Khullar & Babbar, 2011).
Primary neurons in the auditory system include spiral ganglion (SG) nerve cells whose cell bodies are in
the modiolus and whose axons carry sound information to the auditory brainstem. These auditory nerve
fibers provide excitatory inputs to the central auditory system, initially to cochlear nucleus neurons where
excitatory inputs interact with inhibitory neurons, including those with glycine or gamma-amino butyric
acid (GABA) as inhibitory neurotransmitters (Khullar & Babbar, 2011; Lee & Marcus, 2001; Walton et
al., 1998). Age-linked degeneration of SG neurons reduces the number of nerve fibers that can respond to
a stimulus effectively and results in a decline of normal inputs to the cochlear nucleus. This disrupts the
normal balance of excitation and inhibition, decreasing neural coding capabilities in the central auditory
system with age. Inhibition is critical to temporal processing, including masking and binaural coding, in
that the auditory system needs to recover from NB1 in order to process NB2 effectively. By 15 months,
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CBA/CaJ mice are undergoing the initial stages of aging changes in hair cell/SG neuron synapses and
declines in hair cell and neuron numbers. Therefore, ABR peak amplitude and latency are degraded, as
seen in the response changes in the MA group of the present investigation.
Some studies have found that P4 amplitude levels are less likely to show age-related changes
relative to P1 (Boettcher, 2002; Helfert et al., 1999; Sand, 1991). Sand (1991) compared the square-root
transformed amplitude (mean values of right and left ear) level differences for young adult and aged
human subjects and found a 32.7 nV and 5.6 nV disparity for wave I and wave V (the mouse equivalent
to P4), respectively. The findings of Helfert et al. (1999) suggest that a distribution of the excitation/
inhibition equilibrium occurs as GABA+ and GABA- synapses decline in the auditory midbrain (IC) with
age. These excitatory and inhibitory changes interact with the effects of the diminishing size of IC volume
seen in old age. Data from both of these studies are consistent with the theory that the cell count and the
packing density in the IC undergo reductions with age (Allen et al., 2003). Other studies have emphasized
that Wave V/P4 amplitudes decrease with age (Boettcher et al., 1996; Psatta & Matei, 1988). For
example, Psatta and Matei (1988) reported mean Wave I amplitude variations of 0.35 nV and 0.17 nV for
30- and 50-year-old human subjects, respectively and mean Wave V amplitude levels decline from 0.68
to 0.50 nV for the same subject groups. Both peaks display a 0.18-nV difference between the two age
groups. Comparable results can be seen in the present study for P1 and P4 age-related differences, e.g.,
MA mice have mean amplitude values of approximately 3 and 1 µV for P1 and P4, respectively, whereas,
P1 and P4 mean amplitude values for Y mice occur at approximately 6 and 2 µV. Thus, MA amplitude
levels are reduced nearly by half compared with those for Y mice for both P1 and P4. Moreover,
significant differences are seen at 64 ms for both peaks between the age groups (see Figures 6b and 6c).
This supports the idea that P4 is just as much an indicator of the early onset of presbycusis as P1 and is
consistent with the finding that P4 is generated by the lateral lemniscus/IC. Previous studies have shown
that these areas of the central auditory system lose neuron volume and input/output connections with age
(Frisina & Walton, 2006; Konigsmark & Murphy, 1972; Willott et al., 1994).
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Age-Related Effects on ABR GIN Recovery Ratios
Similar to ABR GIN amplitude levels, the recovery ratios increase as the gap duration becomes
longer. The recovery ratios for the Y group were hypothesized to be notably higher than those of the MA
group at shorter gap durations and that gradually, the differences between the ratio values subside as the
gap durations increase. However, this trend is seen only for P4 ratios. P1 ratios start with the two groups
overlapping one another until Y gradually surpasses MA (see Figure 7a). By 64 ms, a difference of
approximately 10 % occurs between the age groups. P4 exhibits recovery ratios that become increasingly
similar with longer gap durations, coinciding with the initial supposition. By 12 ms, values for the Y and
MA groups overlie each other. Boettcher et al. (1996) revealed analogous trends for P1 and P4 for
recovery ratios on com- paring young adult and aged gerbils. For instance, the recovery ratio for P2 was
about 0.40 at 2 ms for both gerbil age groups and this value increased to approximately 1.2 and 0.8 for
young adult and aged gerbils, respectively, at 32 ms. Meanwhile, for P4 recovery ratios, the two groups
varied by nearly 0.10 at 2 ms but the ratio values overlapped one another at gap durations of 8 and 16 ms.
In the present report, the analysis of the P1 and P4 recovery ratios demonstrated that similarities
exist in the way that the Y and MA groups adapt to the WBN stimulus within the auditory system.
Although the ABR amplitudes of Y mice remain consistently higher than those of MA mice, the values
among the groups show some overlap as a function of gap duration, with no more than a 10 % difference
between the Y and MA groups. On the contrary, the consistently decreased amplitude levels and
increased latency values support the theory that the first signs of age-related temporal processing
deficiencies emerge during the mid-life phase. Boettcher et al. (1996) came to a similar conclusion in that
their amplitude recovery ratios showed less of an age difference for young adult and aged gerbils
compared with the absolute amplitude levels. The logic behind this could be that, whereas amplitude
levels considerably decline with age, MA mice still have enough functional hair cells, auditory nerve
fibers and brainstem auditory neurons to generate a physiologically useful NB2 response.
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Latency Values and the Onset of Presbycusis
Latency values in Figure 8a provide additional support for the idea that the first signs of ARHL
occur in middle age, as previously mentioned for the ABR amplitude temporal coding measures.
Specifically, the MA group displayed latency quantities that are longer than those for the Y group for all
of the gap durations. Jerger and Hall (1980) revealed similar results when comparing latencies for human
subjects with ages spanning from 10 to 79 years. Over a period of 25 to 55 years of age, for example,
subjects had latency values that increased about 0.2 ms. Chu (1985) measured the peak latency in humans
ranging from 18 to 76 years of age. P1 mean latency values were reported to be 1.57 ms at ages 20–29
and gradually rose to 1.67 ms by the ages of 50–59. Thus, Chu’s study showed that between the ages of
20 and 59, a 0.10-ms increase occurred in latency. Similarly, Boettcher et al. (1996) observed longer
latency values in aged gerbils. For 8-ms gaps, the mean latency value for aged gerbils was higher than
that for the young adults by more than 0.5 ms. Increasing gap durations reduced this difference to 0.2 ms.
The same 0.2-ms variation can be seen in Y and MA mean latency values at shorter gap durations for our
current report. Conversely, some previous studies suggested that longer latencies in older subjects are
linked to higher hearing thresholds as opposed to age (Beagley & Sheldrake, 1978; Harkins, 1981;
Ottaviani et al., 1991; Otto & McCandless, 1982). Since these studies generally do not cleanly separate
age from audibility variables, whether latency is influenced by sensorineural hearing loss or is a function
of age is still debatable. Lastly, ABR latency changes have been reported to stem from degradations of the
synchrony of auditory nerve fiber and brainstem neural firing and from abnormal changes in the
movement of the basilar membrane (Boettcher, 2002; Khullar & Babbar, 2011).

Summary
Overall, the present study demonstrates that CBA/CaJ mice start to show the first signs of
temporal processing deficits characteristic of ARHL at 15 to 18 months of age. Significant changes are
seen in the MA amplitude levels and latency values for various temporal gap durations. Although these
two ABR response measures declined with age, the recovery ratios between the Y and MA groups do
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indeed show differences but also have some notable parallel features. These neurophysiological results
are consistent with age changes in the structure of the cochlea and auditory brainstem that occur in
mammals; for instance, these functional changes might in part be attributable to the neuron degeneration
that takes place in the cochlea and the brainstem during middle age. In conclusion, the findings of the
present report support the use of ABR GIN responses as a diagnostic physiological biomarker for ARHL,
paving the way for novel future development of acoustic, biomedical, or pharmacological treatments that
might moderate ARHL and that can be administered starting in middle age.
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CHAPTER THREE
HRT MODULATES AGING EFFECTS IN THE AUDITORY SYSTEM
Abstract
Although previous HRT studies on the auditory system have provided information about how
hormones affect hearing, there are still many unanswered questions about hormone treatments and
hearing. Hence, the proposed project was designed to bridge this knowledge gap between what is known
and what is still unknown. For instance, many women who initially start hormone therapy stop for a
number of reasons. However, no study has yet focused on the auditory side effects after HRT is
discontinued. The overall objective for the present study was to evaluate the peripheral and central
auditory systems in female CBA/CaJ middle-aged mice during and after hormone treatments. The female
mice were ovariectomized and placed into 4 HRT groups--- estrogen (E), progesterone (P), E+P and
placebo (Pb). Treatment duration lasted 6 months followed by a recovery period of 1 month. During this
time, electrophysiological hearing tests, such as ABR and ABR GIN, measured auditory hearing
thresholds and temporal processing abilities, respectively, in each of the animals.

Longitudinal

comparisons showed that particularly E and to a lesser extent P treated animals had better auditory
hearing levels relative to the E+P, Pb and male groups during the course of treatment. However, none of
the hormone groups displayed any recovery after treatment stopped. These findings indicate that the
effects of HRT on the auditory system are long lasting.
Introduction
HRT is the most commonly sought out therapeutic intervention to relieve menopausal symptoms.
Studies have shown that HRT alleviates hot flashes/flushes, nausea, dizziness, headache, tachycardia and
palpitations in up to 90% of women (Brenner & Stevens, 2013). These problematic symptoms occur due
to deficiencies in the E feedback inhibition loop, which can result in an influx of gonadotropin releasing
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hormone (GnRH) due to low E levels.

Hormone therapy has been shown to replenish the body with

efficient amounts of E, allowing the feedback system to continue to work efficiently in the reproductive
system. Furthermore, HRT has more recently been proven to have significant influences on the auditory
system. Previous studies have shown that sex hormones can affect DPAOE levels as well as ABR
thresholds and latencies (Caruso et al., 2003; Coleman et al., 1994; Kilicdag et al., 2004; Price et al.,
2009). Kilicdag and colleagues (2004) reported that women treated with E had notably lower mean air
conduction audiometric thresholds and mean bone thresholds than women that didn’t receive any
hormone treatment. Similarly, Al-Mana et al. (2005) evaluated the hearing of women while undergoing
their menstrual cycle and found that hearing sensitivity increased when E levels were at their highest.
These findings coincide with the fact that young females generally tend to perform better in auditory tests
than age-matched male subjects possibly due to the excitatory and neuro-protective effects of E (Jerger &
Hall, 1980; McFadden, 1993, 1998). Contrarily, Price and colleagues (2009) showed that animals treated
with combination therapy (E+P) had significant hearing loss, especially compared to animals that were
only treated with E. Specifically, after only 2 months of treatment, the E+P group had significantly
higher DPOAE thresholds, especially at higher frequencies, than when compared to the baseline values.
None of the other hormone groups displayed statistical differences.

In a clinical research study,

Guimaraes et al. (2006) noted similar results with higher pure-tone audiometric thresholds for women
undergoing combination treatment as opposed to women who weren’t receiving any type of hormone
therapy, or those women receiving E alone. These findings suggested to researchers that P might be
counterbalancing the positive effects of E in the auditory system. Despite this theory, there are no
investigations that have looked into the isolated effects of P in the auditory system, until the present
doctoral project.
While these studies have helped women gain a better understanding of how their hearing will be
affected while undergoing hormone therapy, the influence of sex steroids in the auditory system is still
controversial. For instance, the molecular mechanisms of E in the auditory system are yet to be clearly
determined. There is speculation that E levels help to balance electrolytes in the cochlea and that depleted
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E levels can cause disruption in the maintenance of homeostasis in the inner ear fluids as well as
jeopardize the biochemical integrity of auditory receptor cells, which could possibly include estrogen
receptors (ERs) (Kilicdag et al., 2004; Kucharczyk, 1984). Another theory is that E’s interactions with
ERs activate the production of anti-apoptotic proteins and growth factors, such as FoxO’s (Rudzinski &
Krejza, 2002).

As previously mentioned, P’s effects within the cochlea are still unknown.

Since

progesterone receptors (PRs) aren’t located in the cochlea, scientists have assumed that P’s role in the
auditory system may be more complex than E.

Likewise, the interactions of the E+P combination

treatment (the most common clinical form of HRT) in the inner ear are not fully understood as well.
Previous studies have interestingly shown that E+P helps to prevent osteoporosis and helps to keep
cardiovascular disease at bay. However, the effects of E+P tend to have more of a negative effect on
sensory function by increasing auditory thresholds and latencies.
The present study was designed to help gain a better understanding into the biological
mechanisms of E and P in the auditory system by studying the long-term use of HRT as well as the
aftermath.

Evaluating any lingering side effects may help to provide insights as to how long these sex

hormones might central and peripheral auditory coding.

Although existing evidence from several

previous studies suggest that E+P has a negative impact on the auditory system, while E seems to
improve the quality of hearing, scientists still are not certain what will happen when treatment is
discontinued after long-term HRT use. It was reported that about 50% of menopausal women still
experience some menopausal symptoms up to as much as 65 years of age (Hunter et al., 2012). Premenopause can occur anywhere from about 45 to 55 years of age. Therefore, if a women experiences
menopause at age 45 by the time she is 65 she would have possibly been taking hormone therapy for
approximately 20 years. Can taking HRT over such a long period time have permanent side effects to the
auditory system that may overall improve or worsen the quality of life?
To investigate this in the present study, over the course of 6 months, middle-aged female mice
underwent hormone therapy and had their hearing thoroughly evaluated at various checkpoints using
electrophysiology measures (i.e., ABR, ABR GIN, etc.). Treatment was then discontinued and hearing
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was assessed again to see if hearing function worsened, improved, or remained the same. Furthermore,
the sole influence of P on the auditory system was studied for the first time; as previous reports have only
included E and E+P hormone treatment groups. By studying the individual effects of P, we should be
able to contribute to the understanding of why combination treatment (E+P) is so detrimental to the
auditory system while E alone is not. Overall, information from this investigation will help women make
informed clinical decisions as to whether HRT is the right choice for them or not, including dosage
amount, duration, and timing of treatments.

Methods and Materials
For the present study, 70 CBA/CaJ middle-aged mice were used; 53 females and 17 males.
Baseline testing was performed at 15 months on all of the animals. All of the female mice underwent an
ovariectomy procedure, where both sets of ovaries were removed, once baseline testing was complete.
This was done to ensure that no naturally occurring sex hormones would affect the results. The females
were then randomly placed in hormone treatment groups that consisted of E (n=16, 0.006 mg/day), P
(n=12, 0.40 mg/day), E+P (n=12, 0.40 mg/day + 0.006 mg/day) and placebo (Pb, n=13). It should be
noted that a group of males served as a comparison control group. Hormone therapy was administered in
the form of a subcutaneous slow-release pellet. The pellets were designed to release hormones for a
duration of 3 months and were inserted between the neck and the shoulder of the animals immediately
after the ovariectomy surgery. A second pellet was inserted in the animals after 3 months, ensuring that
the females underwent continuous hormone therapy for a total of 6 months. A 1-month recovery/washout
period took place to see if there were any lingering side effects after HRT was discontinued. Throughout
the course of the experiment, the animals’ hearing was thoroughly tested at different checkpoints:
baseline (before surgery and prior to HRT), 3 months, 6 months, 1 month (post HRT). Auditory testing
consisted of DPOAEs, ABRs and ABR GIN. For the animals that completed the study, samples were
collected and stored for future molecular experiments.
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The same procedures for the auditory tests and data analysis were those used in the Methods and
Materials Section in Chapter 2. Refer to Appendix B for abbreviations.

Results
Hormonal Influences on Absolute Sensitivity of Hearing
Averaged ABR thresholds in Figure 9 depict the changes that each of the hormone groups
underwent during HRT over time (Ftime [9, 208]=21.31, P<0.0001). Very few changes were seen in the E
animal thresholds compared to the other groups (Figure 9). Statistical differences were only seen at 6
kHz and 20 kHz between the baseline and 3 month checkpoints (Refer to Table 2). Meanwhile, E+P
treated animals displayed increases in ABR thresholds during HRT as illustrated in Figure 9c. Significant
differences were seen once treatment ended, especially at 6 kHz, 36 kHz, and for WBN. Interestingly, P
and Pb animals had the worst hearing thresholds among all of the hormone groups during the 6 months of
treatment as well as during the 1-month recovery period. The P group’s thresholds began to significantly
increase as early as 3 months after treatment began, especially for high frequencies. Table 2 shows a
notable increase in the ABR thresholds at 36 kHz and 48 kHz at the 3-month checkpoint. By 6 months,
almost all of the thresholds rose significantly for all of the tested frequencies, relative to the baseline.
Post-treatment ABR thresholds were higher than thresholds during treatment and significantly so
compared to baseline thresholds. Similarly, Pb animals’ auditory function worsened over time during the
experiment. Escalated thresholds were observed 3 months post-ovariectomy surgery and continued to rise
for the remainder of the experiment. Threshold shifts for this particular group were as high as 10 dB for
the higher frequencies. Thus, indicating that the loss of E without receiving HRT had a substantial impact
on Pb animals.

ABR thresholds for the male group displayed modest variances throughout the

experiment (Figure 9e). Considerable differences were seen in the recovery/washout period, similar to
the E+P group. These changes can be attributed to the progression of ARHL for this control group.
Figure 10 shows a comparison all of the hormone groups post treatment (FHRT [4,241]=6.215, P<0.0001).
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No significant differences were found among the groups at the checkpoint; however, the thresholds for
the E animals were consistently lower than all of the other groups.
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Figure 9. ABR thresholds over the course of hormone treatments as well as during the recovery period.
(a) E animals show no significant changes over the course of hormone therapy. Thus indicating that E
possesses protective properties for auditory function. (b) P animals show significant changes at almost all
of the tested frequencies. (c) The E+P group displayed variations in ABR thresholds as early as 3 months.
Notable changes could be seen in this group over time. (d) Pb treated animals’ thresholds changed
drastically over the 6- month time period. Significant changes were observed for all frequencies. (e)
Changes were observed in the male group, more specifically during the recovery period (8 months). The
changes could be attributed to ARHL. It should be noted that statistical differences are a comparison
between the baseline and recovery. Statistical test: 2 way ANOVA followed by Bonferroni; *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001.
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Table 2. ABR statistics for the HRT study subject groups.
Frequency
(kHz)

3

6

12

16

20

24

32

36

48
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Baseline vs. 3 Months
E: ns
P: ns
E+P: ns
Pb: *
Males: ns
E: *
P: ns
E+P:
Pb: **
Males: *
E: ns
P: ns
E+P: ns
Pb: ns
Males: ns
E: ns
P: ns
E+P: ns
Pb: ns
Males: ns
E: *
P: ns
E+P: ns
Pb: ns
Males: ns
E: ns
P: ns
E+P:
Pb: ns
Males: ns
E: ns
P: **
E+P: ns
Pb: ns
Males: ns
E: ns
P: **
E+P: ns
Pb: ns
Males: ns
E: ns
P: ns
E+P: **
Pb: ns
Males: ns

Baseline vs. 6 Months
E: ns
P: ns
E+P: ns
Pb: ***
Males: ns
E: ns
P: *
E+P: ns
Pb: **
Males: *
E: ns
P: *
E+P: ns
Pb: ns
Males: ns
E: ns
P: *
E+P: ns
Pb: *
Males: ns
E: ns
P: **
E+P: ns
Pb: **
Males: ns
E: ns
P: **
E+P: ns
Pb: ***
Males: ns
E: ns
P: ***
E+P: ns
Pb: ***
Males: ns
E: ns
P: *
E+P: ns
Pb: **
Males: ns
E: ns
P: *
E+P: ns
Pb: *
Males: ns
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Baseline vs.
Recovery
E: ns
P: ns
E+P: ns
Pb: ***
Males: ns
E: ns
P: ****
E+P: ****
Pb: ***
Males: *
E: ns
P: **
E+P: **
Pb: ****
Males: **
E: ns
P: **
E+P: *
Pb: ****
Males: **
E: ns
P: ***
E+P: *
Pb: ****
Males: **
E: ns
P: ****
E+P: **
Pb: ****
Males: ***
E: ns
P: ****
E+P: **
Pb: ****
Males: ***
E: ns
P: ****
E+P: ***
Pb: ****
Males: *
E: ns
P: ***
E+P: ns
Pb: ***
Males: **

Table 2. Continued
Frequency
(kHz)

WBN

Baseline vs. 3 Months

Baseline vs. 6 Months

E: ns
P: ns
E+P: ns
Pb: *
Males: ns

E: ns
P: ns
E+P: ns
Pb: **
Males: ns

Baseline vs.
Recovery
E: ns
P: ****
E+P: ***
Pb: ****
Males: **

Shows the statistical differences among the HRT groups for the ABR thresholds at the various
checkpoints at which the animals were tested throughout the study. Statistical test: 2 way ANOVA
followed by Bonferroni pairwise comparisons corrected for multiple comparisons; *P<0.05, **P<0.01,
***P<0.001, ****P<0.0001.

Figure 10. ABR recovery threshold comparisons among the hormone groups. E treated animals had lower
thresholds at 12, 16, 20, 24 and 32 kHz compared to all the other HRT animals. Pb females had higher
thresholds among the HRT groups at 24 and 32 kHz. These data, in conjunction with Figure 9, suggest
that the results of long-term HRT on ABR thresholds are permanent. No statistical differences were seen
among the hormone groups during the recovery period. (E n=3; P n=6; E+P n=7, Pb n=6; Males n=11).
Hormonal Influences on Changes in Auditory Temporal Processing
Longitudinal ABR GIN amplitude values for P1 were compared for each of the HRT groups, as
seen in Figure 11. Similar to ABR thresholds, E treated animals had P1 amplitude levels that minimally
declined over time. For instance, P1 amplitudes ranged from 1.01 mV to 0.85 mV at 16 ms for the
baseline and 6-month checkpoint, respectively. Notable changes were only seen at 64 ms for 3 months
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and 6 months. Interestingly, the P group’s amplitude levels exhibited a gradual decline as treatment
progressed. For instance, amplitude levels dwindle from 1.71 mV to 1.49 mV at 64 ms for the baseline
compared to the 3-month checkpoint. After 6 months of treatment, this value continued to decreased by
0.43 mV, relative to the 3-month value. For this particular group, meaningful differences were seen at
wider gap durations: 32 and 64 ms. Recovery amplitude values for these animals were relatively similar
to 6 month values, which suggests that there is no recovery from P treatment. As presented in Figure 11c,
E+P P1 amplitude levels declined radically after just 3 months of treatment. Baseline values that started
at 1.87 mV were abruptly reduced to 1.11 mV, 3 months after HRT began, for the 64 ms gap interval.
This decline remained reasonably consistent throughout the course of treatment. Significant differences
were seen in gap durations 8, 32 and 64 ms. No recovery was displayed for this group. Contrary to what
was seen with ABR thresholds, E+P had more of a negative effect on ABR GIN amplitude levels than P.
Additionally, differences for P1 amplitude levels in female mice were seen in the Pb group. Decreasing
Gradual values were seen at the smaller gap durations. Note that at 32 ms considerable variations were
seen as early as 3 months. The male group exhibited a sharp regression in P1 amplitude levels for each of
the gap intervals as well. Parallel to Pb animals, statistical differences were seen at 6 months into the
experiment for smaller gap durations; meanwhile, changes were seen as early as 3 months at 32 and 64
ms. The fact that the Pb and the male groups displayed similar trends in P1 amplitude values implies that
ARHL induced auditory temporal processing deficits are occurring in the mice at this particular age--- 18
months. No recovery was observed for any of the hormone treated groups; which suggests that the effects
of long-term HRT are permanent for P1 amplitude levels.
P4 amplitude levels for NB2 in Figure 12 illustrate various changes among the HRT groups. E
treated animals had relatively similar amplitude levels while undergoing HRT and during the recovery
period. Thus, no statistical differences were observed for the E group. P animals displayed amplitude
values that progressively worsened throughout the experiment. For example, baseline P4 amplitude level
of 0.82 mV only decline by 0.13 mV 3 months into hormone therapy for 64 gap intervals. This value
dropped to 0.5 mV by the end of the recovery/washout period. Meaningful changes were seen at 16, 32
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and 64 ms for recovery. More than P1 amplitude levels, P4 amplitude values decreased during the
recovery period. This indicates that P4 amplitudes showed preferential worsening, relative to P1, after
treatments were discontinued. E+P proved to be detrimental to auditory function as displayed in Figure
13c. P4 amplitude levels drastically diminished, especially at longer gap intervals. At 64 ms, the average
baseline level of 0.97 mV dropped to 0.42 mV during the recovery period. Similar to P animals,
amplitudes declined during the recovery period for all of the gap durations, suggesting that E+P worsens
temporal processing abilities in P4 even treatment has ended. Pb animals displayed the most rapid
regression in amplitude levels among the female groups. Notable variations were observed at all of the
gap intervals, particularly for gaps of 16 ms or longer, as seen in Figure 13d. Intriguingly, most of the
recovery amplitude levels resembled those values seen at the 6-month checkpoint. Lastly, the male group
displayed fewer age-related changes than the Pb group for P4 amplitude levels at the shorter gap
durations, but just as severe declines for the longer gaps. Specifically, significant changes occurred at 3
months for 32 and 62 ms. Similar to Pb, these changes are strong indications of temporal processing
deficits characteristic of ARHL. However, in this case, the males show smaller declines at the shorter gap
durations than the E+P and Pb females.
Figure 13 shows comparisons of the amplitude levels for P1 and P4 for all of the HRT groups for
the recovery/washout period.

P1 amplitude levels for E-treated animals were relatively higher in

comparison to the other subject groups. For the shorter gap durations, E animals displayed comparatively
similar P1 amplitude levels to the other groups; however, the difference between the groups increased as
the gap intervals grew wider, i.e., E had more of distinctive effect on P4 amplitude levels, especially for
larger gap durations; whereas, the rest of the subject groups conveyed similar P4 amplitude values for
recovery.

In summary, it appears that E animals consistently presented the best auditory function for

both P1 and P4 amplitude levels, even after treatment was discontinued. There were no statistical
differences displayed among the groups for the recovery amplitudes.
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Figure 11. ABR GIN P1 amplitude levels for NB2 for subject groups during HRT and for the recovery
period. (a) Few changes were observed in E-treated animals during the course of the longitudinal
experiment. Significant changes were only seen at the largest gap interval, 64 ms. (b) The P group
displayed declines while undergoing long-term HRT. (c) Amplitude levels were sharply reduced once
treatment began for E+P animals. Significant changes were seen as early as 3 months at 8, 32, and 64 ms.
(d) ARHL was observed in Pb animals throughout the course of the experiment. These changes could
have been exacerbated due to the removal of E from the body during middle age. (e) The males also
displayed signs of presbycusis throughout the course of the experiment, as steep declines were detected
for P1 amplitude levels. These findings suggest that females treated with E or P retain temporal
processing abilities better than males. No signs of recovery were observed in any of the subject groups.
Statistical test: 2 way ANOVA followed by Bonferroni; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Figure 12. ABR GIN P4 amplitude levels for NB2 for subject groups during HRT and for the recovery
period. (a) Amplitude levels for E-treated animals decline marginally once treatment began. (b) The P
group’s amplitude levels showed a steady decline throughout the advancement of treatment, with the
largest differences seen during the recovery period. (c) E+P animals also displayed a decrease in P4
amplitude levels. Most significant differences were observed during the recovery period. (d) Amplitude
values declined as early as 3 months for Pb animals. This group exhibited the worst regression in
amplitude levels among the female groups. (e) The males showed signs of ARHL at longer gap intervals,
starting at 16 ms. All of the groups, except E displayed changes during recovery, i.e., for these groups P4
amplitudes worsened after HRT was discontinued. Statistical test: 2 way ANOVA followed by
Bonferroni; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Figure 13. P1 and P4 amplitude comparisons for all of the subject groups during the recovery/washout
period. (a) P1 amplitude levels for E treated animals tended to be higher than the other hormone groups
for most gap intervals. (b) The E groups displayed higher P4 amplitude levels than any other group. The
worst recovery values among the female groups were observed for the E+P. There were no statistical
differences among the groups for either P1 or P4 amplitude values. (E n=3; P n=6; E+P n=7, Pb n=6;
Males n=11).
Recovery ratios were also assessed for each group. Recovery ratios evaluated auditory recovery
from NB1 by analyzing responses to the second stimulus, NB2, for gap intervals ranging from 4 to 64 ms.
These ratios were calculating by the following equation: (NB2/NB1)*100 (Williamson et al., 2015). For
P1 recovery ratios, E-treated animals were the only group to show signs of improvement immediately
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after treatment began and even during the recovery period (Figure 14a). Marginal variations were seen
among P1 ratios for the rest of the HRT groups. The only statistical difference was seen for Pb animals at
64 ms between the 3 month and 6 month checkpoints. In contrast to P1, P4 ratios for E animals did not
improve; instead, the values remained comparatively the same as treatment advanced (Figure 15a).
Evident declines were observed in P recovery ratios as early as 3 months. After this point, the values
seemed to level off. A difference was observed for this set of animals at 16 ms between the baseline and
recovery values. E+P animals conveyed signs of degeneration at 6 months with noticeably declining
recovery ratios. Interestingly, a recovery trend was displayed for this group at 4, 8 and 32 ms. Pb and the
male groups had minute discrepancies throughout the experiment. Significant differences were only seen
in Pb animals between the 3 month and 6 month checkpoints for 64 ms.
Figure 16 shows the comparison for the recovery ratios among the hormone groups. E and P
animals tended to display higher recovery ratios for P1 than the other subject groups, especially at the
longer gap durations. Interestingly, both groups demonstrated ratios that were parallel to one another.
Meanwhile, E+P displayed the lowest ratios amid the HRT groups. Pb and the male animals exhibited P1
ratios that were fairly similar to one another. Not too many variations were seen amongst the hormone
groups for P4 recovery ratios. E treated animals as well as the male group displayed slightly higher
recovery ratios compared to any of other groups. Statistical differences weren’t observed for any of the
groups for P1 or P4 recovery ratios.
The last parameter to be evaluated was the response latency, which is the difference between the
onset time the noise stimulus and actual time the response to the stimulus is generated. As seen in Figure
17, latency values for groups E, P and E+P remain parallel throughout the course of HRT. Variations
were only seen in the two control groups: Pb and the males.

Both groups of animals displayed

discrepancies at smaller gap intervals (2, 4, and 8 ms). However, as the gap durations became wider,
latency values began to look more similar for the male group (Figure 17e). Even at larger gap intervals,
the Pb groups presented variations, especially at 6 months. A comparison among the HRT groups after
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Figure 14. P1 recovery ratios for NB2 for HRT groups during and after treatment. Notable differences
were not seen for the recovery ratios for almost all of the groups. The (d) Pb animals were the only group
to show significant changes between the 3 month and 6 month checkpoint at 64 ms. As for (a) E, (b) P,
(c) E+P and (e) the males groups, little to no changes were observed for recovery ratios. Additionally, E
treated animals displayed some signs of improvement in recovery ratios during and after HRT. It should
be noted that signs of recovery after treatment was discontinued was not observed for any HRT group.
Statistical test: 2 way ANOVA followed by Bonferroni; *P<0.05.
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Figure 15. P4 recovery ratios for NB2 during hormone therapy and for the recovery period. Significant
differences were demonstrated for the (b) P group for baseline vs. recovery at 16 ms and for (d) Pb
animals for 6 month vs. recovery at 8 ms. As expected, there were only slight changes in the (a) E group.
Ratio values for the (b) P groups gradually declined with as treatment progressed. Signs of regression
mostly began to take place for the (c) E+P group after 6 months of treatment. Declines were seen for (d)
Pb animals during the recovery period. (e) The male group had ratios that were relatively the same at
larger gap intervals. Auditory recovery was not observed for any of the animals after treatments were
stopped. Statistical test: 2 way ANOVA followed by Bonferroni; *P<0.05.
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Figure 16. P1 and P4 recovery ratio comparison among the hormone groups during the
washout/recovery period. (a) P1 ratios were slightly higher for the E and P animals compared to the other
groups for most of the longer gap durations. As the gap intervals became wider, E+P animals tended to
exhibit lower ratio values than the rest of the groups. (b) Surprisingly, recovery ratios were a bit higher
for E, P and the male group (especially for longer gap durations). No statistical differences were detected
among the groups.
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Figure 17. P1 latency values during the course of HRT and for the recovery period. Trivial variances
were displayed in the (a) E, (b) P and (c) E+P groups. Meanwhile, (d) Pb and (e) the male animals
exhibited more variability in changes in latency values over time. No statistical differences were
observed for any of the groups. Auditory temporal recovery was not seen for any of the groups. For a
more detailed statistical analysis refer to Table A.2. in Appendix A. Statistical test: 2 Way ANOVA
followed by Bonferroni; ****P<0.0001.
the recovery period illustrate that E and P animals the shortest latencies (Figure 18). The Pb and male
groups had the highest latency values for shorter gap durations. And the E+P had the largest latencies
amid the hormone groups, especially at 32 and 64 ms. However, no statistical differences were seen
amongst the groups after recovery from the HRT treatments.
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Figure 18. Post-treatment comparisons for P1 latency values among the HRT groups. Relatively similar
results were observed during the recovery period among the animals groups, except for the shortest gap
durations. The E and P groups tended to displayed lower recovery latency values than any of the other
groups. Pb and the male animals demonstrated problems with temporal processing for smaller gap
intervals. Meanwhile, E+P animals exhibited slightly higher latency values at 32 ms and 64 ms. For a
more detailed statistical analysis refer to Table A.3. in Appendix A.
Subject Body Weight
The body weight for each subject group was assessed during the course of treatment.
Immediately 1 month after HRT began, E treated females’ body weight dropped significantly by 6 grams.
This decline was relatively consistent throughout the 6-month course of treatment, as seen in Figure 19a.
Towards the end of the experiment, the E group lost a total of 9 grams of body weight. Similarly, the
E+P group showed a notable decline in body weight by initially starting at 37 grams and significantly
dropping to 31 grams 1 month after treatment.

The body weight for this group of animals was

comparatively the same throughout the experiment after this point, averaging 31 grams. On the other
hand, P and Pb animals had body masses that decreased gradually over time. For instance, both the P and
Pb group’s body weight decreased by only 3 grams after 1 month. This decline progressively increased to
6 grams and 7 grams for P and Pb, respectively, during the washout/recovery period. The female animals
overall seemed to generally loose weight over time due to hormone treatment as well as to age. On the
other hand, the male’s body weight remained relatively consistent throughout the study with notable
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changes observed only towards the end of the experiment (6 and 8 months). These changes were likely
due to age as well as declining hormone levels.

Thus, indicating that male hormones, such as

testosterone, or other hormones related to physiology metabolism levels may play a role in maintaining a
healthy body weight.
Figure 19b shows the differences seen among the hormone groups at each checkpoint during the
experiment (Fhormone treatment [4, 236]=17.23, P<0.0001). Significant variances were seen immediately after
1 month (30 days) of treatment among all of the groups. The most notable changes were observed
amongst E, E+P and the male group (p<0.0001). These groups continued to have statistical differences
after 3 months (30 days) of treatment, as seen in Figure 19b. However, by 6 months (90 days) only E and
the male group would vary significantly in body mass. Interestingly, during the recovery period, 1 month
after treatment ended, all of the groups’ body weight began to look comparatively similar with one
another. Parallel to Figure 19a, P and Pb females had notably higher body weights than the E and E+P
groups once treatment was administered. The males also had consistently higher body weights than the
female groups throughout the study. It should be noted that all of the groups had fairly similar body
masses at the baseline checkpoint. Overall, these findings suggest that P may play a role in maintaining a
relatively healthy body weight in females; meanwhile, E administered alone may have adverse effects on
some aspects of the body’s metabolism (i.e., decrease in appetite).

Discussion
The present study demonstrated that long-term use of HRT has various effects on the auditory
system, depending on the hormone(s) being administered, and duration of the treatments. E+P animals
displayed exacerbated ABR thresholds as well as reduced ABR GIN amplitude levels immediately after
treatment began. Contrarily, E treated animals exhibited delays in ARHL compared to all of the other
treatment groups, suggesting that the hormone possesses protective properties for the auditory system.
Previous studies have found coinciding results with DPAOE and ABR testing for both aging female

!

52

a

****

**

****

B o d y W e ig h t ( g )

40

**

***

****

50

**
***

*

****

***

**

*

*

B a s e lin e
1 M o n th
3 M o n th s

30

6 M o n th s
R e c o v e ry

20
10
0
E

b

E+P

****
*
****
*

45

B o d y W e ig h t ( g )

P

*

Pb

M a le s

*

*

E
P

40

E+P
Pb

35

M a le s

30

25
0

50

100

150

T im e (d a y s )

Figure 19. Animal body weights declined with aging throughout the course of the experiment. (a) P and
Pb animals exhibited the smallest declines in body weights during the 6 month s of HRT. E and E+P
treated animals displayed significant body weight changes 1 month (30 days) into hormone therapy. The
body weight for both groups continued to progressively decline from there. (b) The body weight for P
animals seemed to be relatively consistent throughout the experiment compared to the other groups. This
group also had the highest body weight among the female groups for the duration of experiment. Pb
animals’ body masses showed a parallel trend to the P group; however, weight values dropped more after
6 months (90 days) of treatment. Interestingly, the E group had the lowest body weight, specifically after
1 month (30 days) of HRT. Statistical test: 2 way ANOVA followed by Bonferroni; *P<0.05, **P<0.01,
***P<0.001, ****P<0.0001.
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humans and mice (Al-Mana et al., 2010; Guimaraes et al., 2006; Price et al., 2009). A novel aspect of the
present investigation was that ABR GIN amplitude levels, recovery ratios and response latencies were
evaluated for P1 and P4 for NB2 for each of the HRT groups to test their temporal processing abilities.
P1 and P4 for NB2 exhibit similarities to wave I and wave V in humans; hence, the reason why these two
peaks were chosen for evaluation here (Boettcher, 2002). Both of the ABR waves are generated from
different parts of the auditory system. Prior studies have suggested that the cochlea/auditory nerve and
the lateral lemniscus/inferior colliculus (IC) produce P1 and P4, respectively. Taking a closer look at how
HRT affects auditory neural processing capabilities, which include neuronal sensitivity with respect to
temporal features of speech processing, will help to gain better insights into the role sex steroids play in
the auditory system and for biologically-relevant sound perception.
E’s Neuro-Protective Properties in the Cochlea
Our study showed positive findings for E-treated animals that can be used to expand on the theory
that this hormone has neuro-protective properties in the auditory system that could possibly prevent or
delay key aspects of presbycusis. As presented above, the E group displayed minimal changes in ABR
thresholds while undergoing HRT (Figure 9a). Additionally, this group of animals consistently had lower
recovery auditory thresholds than all of the other HRT groups (Refer to Figure 10). Price et al. (2009)
observed similar results with ABR thresholds in middle aged female mice treated with E for 4 months
compared to age-matched mice treated with E+P for the same amount of time and their male control
group. It should be noted that the ovaries for the CBA/CaJ female mice used in the Price et al. (2009)
study were intact throughout the course of the treatment. Postmenopausal women treated with E for a
mean of 3.35 ± 2.20 years had consistently lower air conducted thresholds than women who received no
treatment and women who were undergoing combination hormone therapy for 4.13 ± 2.41 years (Kilicdag
et al., 2004). As for P1 and P4 amplitude levels for NB2, minimal changes were also viewed in the
present study. P1 amplitude values for 3 months, 6 months and recovery were essentially the same for the
E group at a majority of the gap durations (Figure 11a). Significant differences were only seen at the
highest gap interval, 64 ms. Likewise, P4 amplitude levels remained comparatively consistent once
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hormone therapy began. These findings support Coleman and colleagues (1994) work with 3-month OVX
rats treated with E that maintained high amplitude levels compared to OVX rats that didn’t receive any
treatment. Analogously, Wharton and Church (1990) observed declining ABR amplitude values between
young women (19-25 years of age) and old females (50-75 years of age). Young women had amplitude
values of 0.41 mV that drastically declined to 0.3 mV in older women for Wave V at 80 dB. Contrarily,
their young and old male counterparts had amplitudes with a difference of only 0.01 mV for Wave V at
80 dB. This steep regression in female amplitude levels in the Wharton and Church (1990) study was
more than likely due to the decrease of E in post-menopausal women aged 50+.
Research has come a long way in explaining the phenomena of E’s benefits in the central and
peripheral auditory system as seen in the previously mentioned studies as well as in our new findings. To
date, there are three theories as to how E preserves auditory function both directly and indirectly. The
most common ideology is that E assists in the regulation of neuron survival, which is an important
component that is lost during the aging process. Estrogen receptor (ER) subtypes, ERα and ERβ, have
been identified in the inner ear, in areas such as the stria vascularis (SV), cochlear blood vessels and spiral
ganglion (SG) type I cells.

ERα has been linked to alterations of cochlear and vestibular sensory

transduction; meanwhile, ERβ is associated with the survival of neurons in the auditory system
(Motohashi et al., 2010). From this knowledge, scientists have proposed that ERβ could possibly play a
significant role in the ascending auditory pathway in transmitting information from the cochlea to the
brain more effectively. It is well known that for hearing transduction, sound waves are converted into
electrochemical signals via the inner hair cells (IHCs). IHCs synapse primarily with type I SG cells,
exciting the auditory nerve, which in return relays sound information to the central auditory regions of the
brain. The synchronization and number of SG cells that respond to a sound stimulus determine the
amplitude and latency of ABR waves. Therefore, attenuating amplitude levels and increasing latency
values are correlated with ERβ degeneration in the auditory system. Previous studies that support this
theory include Hultcrantz et al. (2006) who found that ERβ knockout mice displayed rapid declines in
auditory function as early as 12 months, which eventually led to severe degeneration throughout the parts
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of the brain used for hearing after 1 year. Another theory for E’s contribution to the auditory system is its
involvement in the maintenance of endolymph ionic concentrations and scala media fluid balance
(Garcia-Segura et al., 2001). Disturbances in the electrolyte balance in the cochlea caused by dwindling
E levels could potentially lead to auditory thresholds shifts (Kilicdag et al., 2004). Lastly, researchers
have hypothesized that high levels of E increase cerebral blood flow, which leads to greater physiological
support, including nutrients and oxygen, to auditory cells in the cochlea and the parts of the brain used for
hearing— central auditory system (Shaw et al., 1984).
The results from E therapy for the present report coincide with work done in previous
investigations with hormone therapy, with the additional finding that the effects of E appear to be long
lasting. For example, Rudzinski and Krejza (2002) found that increased E ligand interaction with ER’s
leads to the activation of specific genes and growth factors responsible for anti-apoptotic cellular
responses. Therefore, it is possible that steady levels of E help to keep ER’s intact, which could delay the
degeneration of cochlear cells and auditory neurons. Future studies can be done to investigate which antiapoptotic genes and growth factors E might be activating.
P’s Controversial Impact on Auditory Functionality
Initially, P seemed to have a negative impact on OVX mice as seen in Figure 11b. As soon as
treatment began, ABR thresholds increased drastically by 10 dB for high frequencies at 3 months. This
escalation continued throughout the course of hormone therapy. By recovery, amplitude thresholds shifts
were approximately 20 dB for higher frequencies, relative to the baseline. No recovery was observed.
Interestingly, ABR GIN amplitude values for P1 and P4 at NB2 gradually declined for P treated animals.
For lower gap durations, baseline values and 3 month values were comparatively the same for P1. Signs
of auditory deterioration began to show after 6 months of treatment. Significant differences can be seen
for 6 months and recovery for wider gap intervals, such as 32 and 64 ms. A similar trend could be seen
with P4 amplitude values. However, significant differences were seen only at recovery. Once treatment
ended, P4 amplitudes dropped to nearly 50% compared to baseline values. This is an indication that P
exhibits some type of protection for temporal processing in the brainstem (lateral lemniscus/IC), since P4
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waves are believed to be generated from that region of the brain (Williamson et al., 2015). It should be
noted that P’s overall effects on the auditory system still remain unclear. Very few hormone-based
studies have evaluated auditory function for subject groups treated with only P. However, it can be
speculated that since E has such a positive impact on the auditory system, P must be the negative
component of the hormone duo, E+P, as reported previously. For instance, E+P has been shown to be
detrimental to hearing thresholds by various studies (Guimaraes et al., 2006; Kilicdag et al., 2004; Price et
al., 2009). This theory includes the notion that P acts an inhibitor to balance out the excitatory effects of
E. For instance, high levels of P and its metabolites can potentially activate the synthesis of an inhibitory
neurotransmitter known as γ-aminobutyric acid (GABA), which leads to a surge in inhibitory synaptic
transmission in the brain and the cochlea, disrupting the normal balance of excitatory and inhibitory
drives (Guimaraes et al., 2006; Rogawski, 2003). This rise in inhibition may degrade auditory threshold
sensitivity and supra-threshold responses. Contrarily, E is believed to have the opposite effect, by
decreasing GABA levels in the brain and cochlea to more favorable levels (Ledoux & Woolley, 2005;
Wagner et al., 2001). This logic can explain the negative impact that P had on ABR thresholds for the
present study (Figure 9b). However, favorable auditory responses were observed for the ABR GIN
amplitude levels as well as recovery ratios for P treated animals. Therefore, although P is not consistently
beneficial as E, under certain circumstances P alone may possibly possess some neuro-protection
properties in the auditory system. Consistent with this, several studies have found that P increases
neurogenesis and neuron survival in the brain (Chan et al., 2014; L. He et al., 2011; Si et al., 2013; Si et
al., 2014). For instance, male rats with traumatic brain injury exhibited significantly lower levels of
cyclooxygenase-2 (inflammation) and caspase-3 (apoptosis) after being treated with P (Si et al., 2013).
Additionally, Berent-Spillson et al. (2015) reported that postmenopausal women treated with P had the
same improvements in verbal processing and verbal working memory as women treated with E, for
postmenopausal women that were treated with HRT for a 90-day period. It should be noted that verbal
processing is related to auditory temporal processing. In another neuroscience report, mice treated with
20 mg of P displayed a 6-fold reduction in vacuolated motoneurons and a reduction in nitric oxide
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synthase (NOS) active neurons, both of which are associated with neurodegenerative conditions,
including amyotrophic lateral sclerosis (ALS) (De Nicola et al., 2013). These changes improved certain
symptoms of this disease in the mice over time.
Although quite a few studies have shown the positive influence of P in the brain after traumatic
injuries or neurological diseases, P’s impact on the auditory system is still debatable. Our overall
findings show that P can have negative impacts on ABRs; however, ABR GIN amplitude levels seem to
show P’s abilities to possibly preserve certain aspects of auditory system functionality.

Further

investigation needs to be acquired to gain a better insight into P’s general role in hearing.
Combination Therapy’s Detrimental Influence on Hearing
Prior work has shown that combination treatment has a negative impact on the auditory system.
In the present study, E+P had a detrimental effect on ABR thresholds compared to E and Pb animals.
Threshold values increased by about 10 dB immediately after treatment began, however, they leveled off
during the 6-month period. Recovery thresholds in Figure 10 show that the E+P group has the second
lowest thresholds indicating that this group performed slightly better in ABR’s than all of the female
hormone groups except for E. P1 ABR GIN amplitude values for E+P animals present a sharp reduction
immediately after undergoing HRT.

Amplitude levels were cut roughly in half by the 3-month

checkpoint for all of the gap durations, relative to the baseline. For instance, baseline values that started
at 1.5 µV were drastically reduced to ~0.8 µV after 3 months at 32 ms. Similar to the ABR thresholds,
this decline subsided during the 6 month and recovery period. These findings suggest that the negative
effects of combination treatment occur at a faster pace than compared to P, whose group’s amplitude
values gradually decreased over the course of the experiment (Figure 11). On the contrary, P4 amplitudes
exhibited signs of auditory decline at a steadier rate compared to P1. Significant differences were
highlighted between baseline and recovery values. Interestingly, amplitude levels decreased for most of
the gap intervals after treatment was discontinued.

Similar to the results found with the P group,

combination treatment may have had some marginal auditory benefits while being administered for P4
but not P1. These findings suggest that E+P may have more of long-lasting impact on the auditory nerve
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(P1) as opposed to the IC (P4). Perhaps E+P directly or indirectly regulates the auditory nerve fibers.
Studies have found that dwindling cochlear neurons, seen with aging, can limit the excitatory effect of the
auditory nerve during a noise stimulus. Hence, a less than robust P1 will be generated.
Several reports have shown that E+P affects ABR thresholds as well as amplitude values. Price
et al. (2009) presented statistical differences in ABR thresholds and DPOAE amplitudes in E+P
postmenopausal mice after 4 months of treatment. This particular group was the only set of animals to
display notable changes in DPOAE amplitudes for all frequency ranges. Similar results were conveyed
by Guimaraes et al. (2006) in post-menopausal women. In 2001, Bittar and colleagues attempted to
explain these occurrences by reporting histological changes of inflammation infiltrate and vacuolization
of the SV in guinea pigs treated with E+P. Another theory presented by Zhu et al. (2004) was that
combination treatment might cause a defect in the auditory efferent feedback system from the MOC
complex to the OHC. Nonetheless, there could be a vast number of reasons as to why these changes
occur while undergoing treatment. After all, these animals are experiencing accelerated symptoms of
ARHL, and changes could be transpiring peripherally in the cochlea or centrally in the brain. Future
molecular experiments need to be performed to gain a better understanding of how these hormones
mechanistically interact with one another in the auditory system.
The Influence of HRT on Body Weight
The primary aim of the present study was to observe the long-term effects of HRT on the auditory
system. However, during the process, the body weight for all the hormone groups was evaluated. As
seen in Figure 19, E animals had significantly lower body masses compared to the rest of the animals.
This finding contradicts the scientific reports of E helping post-menopausal women maintain their body
weight. An explanation for this could be that increases in body fat were greater for women taking oral E
as opposed to transdermal E (Santen et al., 2010). It should be noted that the animals in this study were
administered HRT via a time-release pellet that was placed underneath the skin, which could be
considered transdermal.

Remarkably, P and Pb animals relatively maintained their body weight

throughout the course of treatment. However, during the recovery period, Pb animals’ weight notable
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dropped, more than likely due to age. Contrarily, E+P animals upheld somewhat low body masses,
similar to E. This data indicates that body weight variations over the range of the present study had no
significant independent effects on auditory function.

Summary
There were no significant signs of auditory recovery observed for any of the hormone groups. P4
recovery amplitude levels declined significantly compared to only the baseline values for the P and E+P
group. Slight variations were seen between the P4 amplitude values at 6 months and recovery. This
suggests, for example, that P may have minimal benefits for the auditory system; however, its effect only
lasts for the duration of treatment. Contrarily, E seemed to have longer lasting positive results. ABR
thresholds and amplitude levels for recovery were relatively similar to the values seen during treatment.
These findings support previous reports of E having neuro-protective properties via the regulation of cell
survival and anti-apoptosis responses in the auditory system. Future studies will be done to see if
pathways responsible for the regulation of the cell life cycle, such as IGF-1, are influenced by hormone
therapy.
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CHAPTER FOUR
THE INFLUENCE OF ESTROGEN AND PROGESTERONE ON IGF-1 PATHWAYS IN THE
COCHLEA
Abstract
Estrogen (E) is a multi-tasking hormone that not only plays a prominent role in the reproductive
system, but also contributes to various physiological and growth mechanisms within the body. For
instance, studies have shown that E has beneficial effects in the auditory system by delaying signs of
ARHL (Coleman et al., 1994; Guimaraes et al., 2006; Price et al., 2009). Most recently, a link has been
discovered between E and the PI3/AKT pathway, which is an intricate signaling pathway responsible for
the regulation of the cell cycle, including cell death. The PI3K/AKT pathway contains several gene
components, two of which are IGF-1 and FoxO3. Since both genes play a significant role in mediating
cell survival and anti-apoptotic responses, most notably in the brain, the present investigation aimed to
evaluate the expression of IGF-1 and Foxo3 in the cochlea during long-term hormone replacement
treatment (HRT) (in vitro) as well as after treatment was discontinued (in vivo).

For the in vitro

experiments, the cells were placed into four treatment groups E, progesterone (P), E+P and control.
Time-dependent in vitro experiments showed that SVK-1 cells treated with E after 72 hours had notably
higher IGF-1R gene expression levels compared to the other treatment groups, P and E+P. Similar results
were seen with in vivo stria vascularis (SV) tissue samples that were extracted from the cochlear lateral
wall 1 month after 6 months of HRT was discontinued. These findings were further supported by Etreated animals having lower DPOAE thresholds and higher DPOAE amplitudes relative to the other
subject groups (P, E+P Pb and males). Contrastingly, FoxO3 levels were somewhat similar for the HRT
cell groups after 72 hours of treatment (in vitro) and 1-month post treatment (in vivo). Therefore, it is
likely that hormone therapy triggers the up-regulation of IGF-1R in the PI3/AKT pathway, which may
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help to explain the beneficial effects of E in the peripheral as well as the brainstem auditory system, both
during and after HRT treatments.

Introduction
Scientists have observed the neurotropic effects of estrogen (E) outside of the reproductive
system for decades. The interest initially began when morphological sex differences were observed in the
brain, which showed evidence of females being more prone to certain neurological disorders compared to
males due to declining E levels, associated with aging.

For instance, a negative correlation was

discovered between E levels and Alzheimer’s disease (AD) when postmenopausal women treated with E
were less likely to develop AD with age (Paganini-Hill & Henderson, 1996). Similar studies have
indicated that this delayed onset of certain neurological conditions associated with aging is due to E’s
ability to prevent axonal/dendritic pruning as well as promote cell survival and synaptic plasticity
(Duenas et al., 1996; Garcia-Segura et al., 2001; Villa et al., 2016). Additionally, growing evidence
supports the possibility of a co-dependent relationship between E and IGF-1 in the nervous system
(Azcoitia et al., 1999; Duenas et al., 1996; Fernandez-Galaz et al., 1997). IGF-1 is associated with the
complex cell-signaling PI3/AKT pathway, which regulates cell survival, angiogenesis, and cell
proliferation via the phosphorylation of AKT. Duenas and colleagues (1996) found that simultaneous
additions of both E and IGF-1 to developing hypothalamic cells displayed beneficial results compared to
when the components were individually administered to the cells, suggesting that both of these molecules
may be acting through a common mechanism. Fernandez-Galaz et al. (1997) reported that IGF-1 and E
interact with one another to activate astrocytes of the hypothalamic arcuate nucleus, which has been
linked to glial and synaptic plasticity. Furthermore, E’s protective properties are dependent on the
accessibility of IGF-1R to its ligands.
Another essential component in the PI3K/AKT pathway that is related to activation by E is
transcription factor, forkhead box O3 (FoxO3) (Olivieri et al., 2014; Pollanen et al., 2010). While FoxO3
assists IGF-1 by inhibiting pro-apoptotic genes and promoting cell survival via the IGF-1 pathway, this
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transcription factor may also be responsible for removing toxins from the cell via the up-regulation of
autophagy-related genes (Mammucari et al., 2007; Vasudevan & Garraway, 2010). This helps to create a
healthy environment for the cell to maintain homeostasis and overall integrity; thus, prolonging the signs
of aging in the body. For instance, Olivieri and colleagues (2014) demonstrated that MCF-7 cells treated
with E had significantly higher FoxO3 levels than untreated cells. Similar results were seen in the
skeletal muscle of postmenopausal monozygotic twins undergoing discordant E replacement therapy.
The study concluded that high FoxO3 levels from E therapy in the skeletal muscle tissue resulted in
similar beneficial effects as that from resistance-type physical training, possibly due to FoxO3’s abilities
to remove waste products within the tissue. Likewise, Renault et al. (2009) proved that high FoxO3
levels are associated with the self-renewal and homeostasis of neural stem cells (NSC) in mice. The
quantity of NSCs is extremely limited and declines significantly with aging due to oxidative stress and
apoptosis. FoxO3 inhibits apoptotic-inducing genes, such as TRADD and Fas ligand, in the PI3K/AKT
pathway to help preserve these cells to maintain cognitive function; thus, reducing the chances of
neurodegenerative diseases such as Alzheimer’s and other forms of dementia. Overall, both genes appear
to be vital in the survival and maintenance of cells, which would improve the quality of life.
From the previously mentioned studies, it can be concluded that E has a significant influence on
the PI3K/AKT pathway in various parts of the body. Could it be possibly that E has this same effect on
the IGF-1 pathway in the auditory system? Recently, our research team discovered that E plays a
significant role in the peripheral and central auditory system by deferring characteristics of age-related
hearing loss (ARHL) (Guimaraes et al., 2006; Price et al., 2009). Longitudinal studies show that Etreated aging mice had lower ABR thresholds as well as higher ABR GIN amplitude levels than animals
that didn’t receive any type of treatment after 6 months (Refer to Chapter 3), suggesting that E preserves
cells in the cochlea, which may help to maintain auditory function over time; however, the biological
mechanisms as to how this occurs are still not fully understood.
The purpose of the present study was to evaluate the relationship between sex hormones and the
PI3K/AKT pathway in the aging cochlea. IGF-1R and FoxO3 expression levels were examined during
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hormone treatment to determine whether these genes play a role in survival of cochlear cells and
ultimately, prolonging key aspects of presbycusis. Over the course of this investigation, in vitro SVK-1
cells underwent HRT in a time-dependent manner of 4, 12, 24, 48 and 72 hours. The cells were
categorized into 4 hormone groups: E, progesterone (P), E+P and control. In vivo studies were also
performed on extracted cochlea SV tissue samples that were obtained from animals that discontinued
long-term HRT for 1 month. In the study, we found that E-treated in vitro cells had notably higher IGF1R and FoxO3 gene expression compared to P and E+P treated cells. Additionally, E animals had a
higher IGF-1R gene expression relative to the other subject groups (P, E+P, Placebo [Pb] and males)
during the washout/recovery period. DPOAE results from hormone treated animals coincided with these
molecular findings with E animals maintaining lower thresholds compared to the other subject groups.
Optimistically, the discoveries from this experimentation will help to gain better insight as to how E
preserves cellular functionality in the aging auditory system via neuro-protective properties, which could
lead to future enhancements in therapeutic solutions for preventing or treating key aspects ARHL.

Methods and Materials
Distortion Product Otoacoustic Emissions (DPOAEs)
Ipsilateral acoustic stimulation from two primary pure-tone frequencies (f1 and f2) was performed
on anesthetized (ketamine/xylazine 120 and 10 mg/kg, respectively) CBA/CaJ mice using a Tucker Davis
(TDT, Alachua, FL) BioSig System III. A customized coupler attached to a microphone/speaker system
was placed inside the ear canal (near the tympanic membrane) of each mouse to measure the otoacoustic
emissions generated by the motility of the outer hair cells. From here, the magnitude of f1, f2, 2f1-f1
(amplitude) and the noise floor were determined for frequencies ranging from 6.2 to 43.5 kHz. It should
also be noted that the pure tone frequencies had a differing factor of 1.23 and were presented at moderate
intensity levels, 55 and 65 dB SPL, correspondingly.
For more information about the CBA/CaJ mice and the protocol used for hormone therapy
treatments, refer to the Methods and Materials Section in Chapter 3.
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Cell Culture and Hormonal Treatments
SVK-1 epithelial cells derived from the SV of the P14 Immortomouse (obtained from Dr.
Federico Kalinec, Univ. South. Cal.) were utilized. DMEM medium (Corning Manassas, VA) with 10%
FBS was used to proliferate the cells. Initially, the SVK-1 cells were incubated at 33°C in a humidified
10% CO2 atmosphere in a proliferation stage. At least 24 hours before treatment, the cells were then
placed in a differentiation setting of 39°C and 5% CO2 to ensure the cells successfully matured to SVK-1
epithelial cells in serum-free DMEM. Once the optimal dosage was determined, the cells received 10 nM
of hormone treatment (E, P or E+P) for various time durations, which included 4, 12, 24, 48, and 72
hours. 10 nM was the optimum dosage for HRT treatment for cells according to previous studies (Duenas
et al., 1996; Olivieri et al., 2014). It should be noted that cells were administered HRT at a confluence of
~ 80% for treatment durations of 24 hours or less. Hormone therapy lasting more than 24 hours began
when a confluence of ~30% was obtained to increase the number of healthy cells that would be collected
once treatment ended.
PCR Experiments
Following treatment, the cells were washed and extracted using the protocol from the RNeasy
Mini Kit (Qiagen). SV tissue samples that were extracted from the cochlea of animals from the HRT
study were also used for the following experiment (Refer to Chapter 3 Methods and Materials Section).
The samples were placed in RLT Buffer and then extracted using the same protocol as the SVK-1 cells,
previously mentioned. The samples were categorized according to the treatment each animal received: E
(n=4, 0.006 mg/day), P (n=4, 0.40 mg/day), E+P (n=4, 0.40 mg/day + 0.006 mg/day) and placebo (Pb,
n=3). 50 ng for each of the following RNA samples was then used to synthesize 20 uL of cDNA using an
iScript cDNA kit (Bio-Rad Laboratories; Hercules, CA). Once the sample mixtures were made, they
were incubated for 5 min at 25° C (priming), 20 min at 46° C (reverse transcription) and 1 min at 95° C
(RT inactivation).

Primer sequences used to detect the genes were as follows: IGF-1R, 5’-

TTGCCTAAAACTGAAGCTGA-3’ and Foxo3, 5’-GTTCAATGGGAGCTTGGAAT-3’. Quantitative
PCR (qPCR) experiments were performed by creating a master mix using the following primers, SSoFast
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EvaGreen (Bio Rad, Hercules, CA) and the cDNA samples. The samples were then placed in a CFXTM
Real Time PCR system to generate a quantitative analysis of the gene expressed in both SVK-1 cells and
SV tissue samples.
ELISA Assay
Blood samples were extracted from animals undergoing HRT treatment for 6 months, as
previously discussed in Chapter 3. The blood was set to clot in lukewarm water for ~15 min and then
centrifuged for 20 min to allow separation. The serum was then collected and stored at -80° C for future
use. IGF-1 concentrations were quantitatively assessed following the manufacture’s protocol for an IGF1 Quantakine ELISA Kit (R&D Systems, Abingdon, UK).
For abbreviations refer to Appendix B.

Results
Longitudinal DPOAE hearing tests were performed on the animals for each of the subject groups
during the 6 months of hormone treatment and 1 month washout/recovery period. Averaged DPOAE
thresholds show that E+P and male animals had the most significant changes compared to the other
subject groups, as seen in Figure 20. For example, E+P animals exhibited high thresholds at 12, 16, 28,
32 and 36 kHz after undergoing 6 months of treatment, relative to the baseline (FHRT [21,106]=3.115,
P<0.001). Interestingly, during the recovery period, hearing thresholds began to decline for mid- to -high
frequencies, suggesting some type of improvement once treatment ended. An example of this can be seen
at 28 kHz when the DPOAE threshold fell from 65 dB SPL at 6 months to 52 dB SPL during the recovery
period.

No significant variances were observed between E+P baseline and recovery thresholds.

Contrarily, the males exhibited signs of ARHL due to gradual increases in DP thresholds, with significant
differences detected during the recovery period, relative to the baseline (FHRT [21,115]=3.6, P<0.001).
Thresholds values notably increased at almost all of the frequency levels for the males during this time.
Pb animals also displayed signs of presbycusis most noticeably at the middle frequencies. Intriguingly,
the E and P groups’ threshold values didn’t vary much after 6 months of HRT. The values for 6 months
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and recovery overlap one another for both groups at most of the frequency levels. Although, a few
significant differences were observed at 6, 36, and 44 kHz for E animals and only 6 kHz for the P mice.
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Figure 20. DPOAE thresholds for CBA/CaJ mice during the course of long-term HRT and 1 month
recovery period. (a) E animals exhibited little to no changes during the course of treatment. Significant
differences were only seen at 3, 32 and 44 kHz between baseline and 6 month thresholds. (b) Animals
treated with P had thresholds elevated the most at 3 kHz at 6 months and during the recovery period,
relative to the baseline. (c) E+P animals had thresholds that escalated significantly after 6 months of
treatment. Interestingly, threshold values improved during the recovery period, suggesting that auditory
function improved once treatment ended. (d) A gradual increase can be seen in the Pb and (e) male
thresholds, suggesting these untreated animals were showing signs of ARHL during the course of the
experiment that continued during the recovery period. Statistical test: 2 way ANOVA followed by
Bonferroni post-hoc pairwise comparisons; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. NF denotes
the noise floor during DPOAE testing.
A comparison among all of the subject groups at 6 months and the recovery (Figure 21) reveal
that E animals had the lowest threshold values at most of the f2 frequency levels throughout the
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experiment. In contrast, the E+P group had highest threshold values at the 6 months checkpoint; but,
where essentially replaced by the Pb group during the recovery period (Refer to Figure 21b). Pb animals
clearly displayed increased thresholds from 12 to 32 kHz. These data further support the idea that E+P
animals displayed some type of recovery for DPOAE thresholds once HRT was discontinued.
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Figure 21. A comparison of the DPOAE thresholds among the subject groups at 6 months and after the
recovery period show no major differences. (a) At 6 months the E group maintains slightly lower
thresholds for most of the f2 frequency levels. In contrast, the E+P group had somewhat higher
thresholds than the rest of the subject groups from 12 to 46 kHz, indicating that auditory function is
deteriorating under this type of hormone treatment. (b) During the recovery period, overall, the E group
tends to have lower thresholds compared to the rest of the subject groups. Concurrently, the Pb group’s
thresholds are slightly elevated, so the they had the worst hearing thresholds at this point It should be
noted that the E+P group shows signs of some improvement in their threshold values once treatment has
ended. NF denotes the noise floor during DPOAE testing. (E n=4; P n=5; E+P n=5; Pb n=5; Males n=5)
Averaged amplitude levels for the subject groups displayed similar trends with the highest
amplitude values seen at frequency levels ranging from 12 to 28 kHz (Refer to Figure 22). Pb and the
males were the only groups to show considerable changes in the recovery/washout period. Pb animals
had amplitude levels that declined after 6 months of treatment compared to the rest of the hormone treated
females (FHRT amplitude [7,124]=9.843, P<0.0001). For instance, Pb amplitude levels dropped from 29 to 17
dB SPL from the baseline to the recovery period, correspondingly, at 20 kHz. This could be due to the
fact that the Pb animals underwent an ovariectomy procedure immediately following baseline testing.
The lack of E in the body over the course of the experiment could have possibly had an effect on auditory
function. Note that significant differences were seen at 20 and 28 kHz during the recovery period. The
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male group had amplitude levels that progressively decreased over time, similar to the DPOAE thresholds
observed in Figure 20e (FHRT amplitude [7,11]=12.77, P<0.0001). Significant changes were seen only at 16
and 28 kHz at the recovery checkpoint. Interestingly, the E, P, and E+P group exhibited minor changes in
amplitude levels throughout the experiment, which could possibly indicate that the hormone treatment
helped to maintain DPOAE amplitude levels over time.
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Figure 22. DPOAE amplitudes for CBA/CaJ mice during the course of long-term HRT and 1 month
recovery period. Similar trends in (a) E, (b) P, and (c) E+P animals’ amplitude levels displayed little to no
changes over the course of the experiment, with E showing the least declines. The (d) Pb and (e) male
groups were the only groups that showed significant changes during the recovery period, relative to the
baseline. Interestingly, female animals receiving some type of hormone therapy (E, P or E+P) seemed to
have been protected from some auditory degeneration over time, in this case. Statistical test: 2 way
ANOVA followed by Bonferroni post-hoc pairwise comparisons; *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001. NF denotes the noise floor during DPOAE testing.
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Figure 23 displays a comparison of the amplitude levels among the subject groups at 6 months of
hormone treatment and for the 1 month recovery period. As expected, E animals demonstrated high
amplitude levels at both checkpoints, further supporting the theory that E has a beneficial effect on the
auditory system. E+P animals showed the lowest amplitude levels after 6 months of HRT. By the
recovery period, the P and Pb group had the lowest amplitude values, as seen in Figure 23b. No
statistically significant differences were detected among the groups.
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Figure 23. A comparison of the DPOAE amplitude levels among the subject groups at 6 months and the
recovery period showed few differences. As expected, E animals tended to have higher amplitude levels at
both (a) 6 months and (b) the recovery period compared to the rest of the subject groups. Slightly lower
amplitude values were observed for E+P and P animals for most frequencies at 6 months. After, the
recovery period, Pb animals tended to have the lowest amplitude values accompanied by the P group, for
higher frequencies. NF denotes the noise floor during DPOAE testing. (E n=4; P n=5; E+P n=5; Pb n=5;
Males n=5).
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Overall, the DPOAE results show that E had the most positive impact on the auditory system;
meanwhile, E+P appears to accelerate the signs of presbycusis. Previous findings from Chapter 3 also
coincide with these results. For example, ABR thresholds were significantly lower for E treated animals
during long-term HRT; meanwhile, P and E+P animals had notably higher thresholds, with significant
changes within each group over time compared to the other subject groups. It was hypothesized that E
would increase IGF-1R and FoxO3 gene expression levels in cochlear cells. This increase in gene
expression would promote resistance to oxidative stress and apoptosis, therefore delaying key features of
ARHL, as previously mentioned.

Therefore, a quantitative analysis of IGF-1R and FoxO3 gene

expression was performed on SV tissue samples (in vivo) and SVK-1 cells (in vitro) to determine how sex
hormones regulated these genes in the cochlea.
Figure 24 shows that SV tissue samples from E treated animals had significantly higher IGF-1R
levels, by approximately 3-folds, compared to the rest of the groups in the study (FHRT [5,10]=6.50,
P=0.0061). The E+P and male groups had similar IGF-1R fold expressions at 0.96 and 1.06, respectively,
while the remaining groups had expressions that were notably less than 1. The Pb and control female
(CF) groups had the most significant differences, relative to the E group, among the other animals. This
is an interesting finding due to the fact that neither of these female groups underwent any type of hormone
treatment. Therefore, it is possible that lack of HRT, during the aging process, decreases IGF-1R levels.
Conversely, FoxO3 expressions were relatively similar among all of the groups, with expression levels
ranging from 0.76 (CF) to 1.26 (P) (FHRT [5,11]=1.43, P=0.2858). It is important to note that these are the
gene expression values 1 month after HRT was discontinued.
Additionally, serum IGF-1 expression levels were taken from animals that underwent HRT for
the duration of 6 months, followed by the 1 month recovery period, which are shown in Figure 25.
Among the female hormone groups, E and P animals had higher levels of IGF-1 levels compared to E+P
and Pb mice. Significant differences were seen between the E+P, Pb and male control groups. These
findings indicate that hormones have somewhat of an impact on IGF-1 levels, albeit no significant
differences were observed for any of the females.
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Figure 24. Post-treatment IGF-1R and FoxO3 expression levels in SV tissue samples. (a) E animals had
the highest IGF-1R fold expression levels among the subject groups. Interestingly, Pb and *control
female (CF) animals tended to have lower gene expression values, and notable differences were found
between E and all of the other groups. (b) FoxO3 gene expression was comparatively similar among the
animal groups. The P group tended to have the highest expression at 1.26 and the CF had the lowest at
0.76. It can be noted that the CF group had the lowest expression levels for both genes. Statistical test: 1
way ANOVA followed by Bonferroni; *P<0.05, **P<0.01. Statistical differences among the subject
groups are in reference to E. (E n=3; P n=3; E+P n=3; Pb n=3, Males n=3; CF n=3) *The control
females still have their ovaries intact and did not undergo any type of HRT.
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Figure 25. Post-treatment IGF-1 concentration levels in the serum of HRT mice. E and P have higher
levels of IGF-1 compared to E+P and Pb female animals. Statistical differences were found between the
males and the E+P and Pb groups. No significant differences were observed among the female HRT
groups. Statistical test: 2 way ANOVA followed by Bonferroni; *P<0.05.
In-vitro studies were also performed to observe the expression of IGF-1R and FoxO3 during the
course of HRT. SVK-1 cells were treated with E, P or E+P and were evaluated in a time-dependent
manner: 4, 12, 24, 48, and 72 hours. (Untreated cells are denoted at 0 hours and served as the control.) E
treated cells had IGF-1R levels that distinctly increased with time, as seen in Figure 26a.

Fold

expressions that were initially 0.56 at 4 hours rose to 2.21 towards 72 hours of E treatment, which is more
than twice the starting value. SVK-1 cells treated with P exhibited smaller changes in expression during
hormone therapy.

Gene expression levels spanned from 0.80 to 1.55 for 4 hours and 72 hours,

respectively. Similar to E and P, E+P treated cells’ IGF-1R levels increased once treatment began.
However, gene expression started to decline, most noticeably after 72 hours of HRT. For instance, at 4
hours E+P cells had gene expression levels of 0.68 that proliferated to 1.5 at 24 hours and then dwindled
to 1.02 at 72 hours. It is possible that IGF-1R levels would further decline for time periods greater than
72 hours for this particular group. These findings indicate that E plays a key role in amplifying the
expression of IGF-1 in the cochlea; meanwhile, combination treatment (E+P) has a negative effect, which
could contribute to degeneration in the auditory system. It should be noted that all of the cell groups had
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gene expressions that marginally declined, relative to untreated cells (0.86), during the first few hours of
treatment.
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Figure 26. In vitro quantitative IGF-1R gene expression in SVK-1 cells after different time intervals for
the duration of HRT. (a) IGF-1R gene expression tended to increase once E treatment began. The
expression more than doubles after 72 hours of hormone therapy. (b) P treated cells had IGF-1 expression
levels that marginally increased over the course of the experiment. By 24 hours, the gene expressions
seemed to have plateaued. (c) SVK-1 cells treated with E+P displayed gene levels that originally
intensified; however, these values began to decline after 72 hours of HRT. It is possible that expression
would be reduced to the value of the untreated cells or worst if E+P treatment progressed longer than 72
hours.
FoxO3 gene expression was also evaluated in hormone treated SVK-1 cells, as seen in Figure 27.
Untreated cells had an average FoxoO3 expression value of 3.14. Intriguingly, all of the HRT cell groups
decreased significantly immediately after treatment began; however, only E-treated cells displayed
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statistical differences over the entire time course of hormone therapy (Figure 27a). For instance, SVK-1
cells undergoing E therapy had FoxO3 levels that were reduced to a value of 0.51 at 4 hours. The gene
expression gradually changed to 1.64 by 24 hours, which is about half of the untreated cell’s FoxO3
expression value. 48 hours later gene levels began to decline once again, reducing the value to 0.93 by
the end of the experiment. This similar pattern was observed less dramatically in P and E+P treated cells.
SVK-1 cells treated with P had FoxO3 gene expression levels that escalated from 0.54 to 1.91 in a span of
24 hours. Nonetheless, this value was reduced to 1.5 after 72 hours of hormone therapy. It can also be
observed that FoxO3 levels somewhat plateaued after 48 hours for this group. E+P cells displayed FoxO3
expressions levels that elevated to 2.42 at 24 hours from an original value of 0.66 once treatment began.
Likewise, this number dropped to 1.73, a difference of 0.69, towards the end of the experiment. These
results strongly suggest that E and P modify FoxO3 levels in the cochlea. However, the reason for the
variability in the gene expression at the different time points is not quite fully understood. There is a
possibility that HRT down-regulates FoxO3 gene levels, seeing that at 72 hours of treatment all of the
hormone groups had diminishing expression values. Among the groups, P and E+P had the highest
FoxO3 expression levels throughout the experiment, with values of 1.5 and 1.73, correspondingly. This
indicates that E not only maintains lower FoxO3 levels in the auditory system over time, but does so more
effectively than P.

This reduction in FoxO3 expression may activate another component in the

PI3K/AKT pathway to assist cochlear cells with neuro-protective activities. Further testing should be
done to determine whether the declines in expression seen during treatment improve or worsen for longer
time periods.
Similar to in vivo SV samples results, E treated SVK-1 cells had the highest IGF-1R gene
expression after 72 hours of treatment compared to other hormone groups, as seen in Figure 28a. This
coincides with previous reports of E’s long lasting effect on the auditory system, as discussed in Chapter
3. Additionally, E-treated cells displayed high levels of IGF-1R both during and after HRT (Refer to
Figures 24a and 28a). E+P cells had the lowest IGF-1R expression among the hormone groups during
treatment. However, Figure 24a shows that E+P levels are slightly higher than P, which could possibly
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indicate some type of recovery once treatment had been discontinued. As for FoxO3 levels, there were no
significant changes observed after 72 hours of HRT in any of the hormone groups, which is similar to
post-treatment FoxO3 gene expression levels for in vivo SV samples (Figure 24b). It should be noted that
E-treated cells had the lowest FoxO3 levels while E+P SVK-1 cells had the highest gene expression at 72
hours among the groups. These findings support the theory that IGF-1R and FoxO3 have an inverse
relationship with one another during sex hormone therapy.

a

b

c

Figure 27. In vitro quantitative FoxO3 gene expression in SVK-1 cells after different time durations of
HRT. (a) E, (b) P, and (c) E+P displayed similar trends, in which FoxO3 expression levels decreased after
4 hours of treatment, increased by 24 hours, and then abruptly declined at 48 hours. Statistical differences
were observed for the (a) E group throughout the course of HRT. E+P treated cells displayed the highest
FoxO3 folded expression among the hormone groups at 24 hours, approximately bringing gene levels
back to their primary state before treatment. Meanwhile, E cells revealed the lowest gene expression
values compared to P and E+P, most notably at 72 hours. The gene expression levels appeared to plateau
at 48 hours for P-treated cells. The statistical differences are relative to the untreated cells at 0 hours.
Statistical test: 1 way ANOVA followed by Bonferroni; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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a

b

Figure 28. Comparison among the hormone treated cell groups after 72 hours of HRT for IGF-1R and
FoxO3 gene expression. (a) E proves to have the ability to maintain high IGF-1R levels over time;
meanwhile, E+P cells display gene expression levels that continue to decline at 72 hours, causing this cell
group to have the lowest expression. A significant difference was observed for E+P group relative to the
E group. (b) Although the gene expression levels for FoxO3 initially increased at different values for all
of the groups, at 72 hours were no significant differences. It should be noted that E-treated cells
displayed lower FoxO3 levels than both P and E+P SVK-1 cells. Statistical test: Welch’s t test followed
by Bonferroni; *P<0.0332.
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Discussion
Hormone Therapy Increases IGF-1R Gene Expression for Neuro-Protection
As hypothesized, E proved to have a beneficial effect on IGF-1R expression in the cochlea. For
example, I found that IGF-1R levels progressively increased from 0.56 to 2.21 in E treated SVK-1 cells
during a 72 hour time span. Even more interesting, was the in vivo finding that IGF-1R expression levels
were still significantly high 1 month post-treatment in SV samples extracted from the cochlea of E mice
compared to the rest of the subject groups (Figure 24a). These results coincide with the E group’s ability
to maintain lower DPOAE thresholds and higher DPOAE amplitude values during long-term HRT,
indicating that E and IGF-1R have a co-dependent relationship with one another. P treated cells had IGF1R levels that marginally increased. At 72 hours of hormone treatment, the IGF-1R expression only
increased by 0.75 for this cell group. The E+P cell group had IGF-1R levels that initially increased over
time, similar to E and P cell groups; however, the gene expression started to considerably decline at 72
hours (Figures 26c and 28a). These results could help to explain why DPOAE thresholds for E+P
animals dropped significantly while HRT was administered. Interestingly, the threshold values somewhat
improved during the recovery period, most specifically at mid-to high frequency levels. This finding
could plausibly explain why post-treatment SV tissue samples of E+P mice had IGF-1R levels that were
comparable to P even though in vitro experiments show that IGF-1R levels decline after long periods of
combination treatment. Therefore, it is possible that some of the negative effects E+P has on the auditory
system during treatment could be reversed once HRT is discontinued.
IGF-1 serum levels taken from mice 1 month post-treatment showed that although there were no
significant differences within the female groups, E and P had slightly higher values compared to E+P and
Pb animals. These results are parallel to the in vitro findings where E and P treated cells had higher IGF1R expressions compared to E+P cells as well as untreated cells after 72 hours of HRT. However, there is
a slight contradiction when comparing these data with the results from my in vivo experiments, where
recovery IGF-1R levels for E animals are significantly higher than the remaining subject groups,
including P. Surprisingly, the male groups had significantly higher IGF-1 serum levels than E+P and Pb
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animals (Figure 25). Additional data from my in vivo experiments revealed that the male group has
higher IGF-1R expressions than both E+P and Pb animals. Similar results were seen when Pollanen et al.
(2010) compared IGF-1 serum levels of menopausal women undergoing HRT to those that were receiving
any type of treatment and found no significant differences.

However, this research team did find

meaningful differences in the expression levels of genes associated with the IGF-1 pathway (i.e. IGF-1,
AKT1, and FoxO3) between HRT users and non-HRT users.
The findings from this dissertation support the growing evidence that E has a positive relationship
with IGF-1R, in order to manage oxidative stress and promote cell survival. For instance, Olivieri and
colleagues (2014) found that IGF-1R expression levels doubled in MCF-7 cells when E dosages were
raised from 10 nM to 100 nM. This increased expression of IGF-1R proved to have beneficial value on
cell signaling, mobility, and muscle power in the skeletal muscle of postmenopausal women undergoing
HRT. The study concluded that E increases activity in the IGF-1 pathway, significantly delaying the
atrophy of skeletal muscle in HRT users. Therefore, the results of the present study can be interpreted
that the high IGF-1R expression levels that I observed in E treated SVK-1 cells were protecting cochlear
cells from degeneration. This is further supported by the fact that various studies have found that E
improves and maintains auditory function through neuro-protective properties. One of the main theories
contemplated as to how this occurs is estrogen receptor β’s (ERβ) association with the survival of neurons
in the cochlea. For example, previous work suggest that ERβ may play a role in the synchronization of
responsiveness of cells that respond to a noise stimulus in the auditory system, which can have an
influence on auditory physiological thresholds and amplitude levels. The more in-synch and the greater
the number of cells that respond to a stimulus will lead to lower thresholds and higher amplitude levels.
Prior studies have shown that ovariectomized (OVX) mice treated with E experience an up-surge of
estrogen receptors (ER) in the cochlea (Hultcrantz et al., 2006; Motohashi et al., 2010; Stenberg et al.,
2003). Perhaps there is cross-talk specifically between ERβ and IGF-1R pathways in the auditory system.
A pioneering study executed by Toran-Allerand and colleagues (1988) showed that cultures of the
olfactory bulb, hypothalamus, preoptic area and cerebral cortex treated with E and high levels of insulin
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exhibited significant increases in neurite outgrowth. The increase in neuronal growth was limited to areas
that only had ERs. Quesada and colleagues (2007) found that SNpc DA neurons found in the brain were
immunoreactive for ERβ and IGF-1R, which helped to explain why E’s neuro-protective effects were
related to IGF-1. It should be noted that ERα was not identified in this particular neuron. Furthermore,
primary cortical neurons treated with the excitatory neurotransmitter glutamate to induce neuronal death,
exhibited signs of neuro-protection with decreased cellular lactate dehydrogenase (LDH) levels after
being administered E (Singer et al., 1996). LDH levels increased in pre-treated E cells given Tamoxifen
(the major blocker of ERs used clinically) over a 24 hour period, reversing any signs of neuro-protection.
While the notion that ERβ has a co-dependent relationship with IGF-1R may be speculative, what
is known for certain, as confirmed by the auditory system in the present investigation, is that E activates
the IGF-1 pathway. Once IGF-1 binds to its receptor, AKT becomes phosphorylated and triggers various
pathways within the cell. The fact that E activates so many biological events, leads to a number of
possibilities of which downstream pathways are involved in this neuro-protection in the auditory system.
Hopefully, the findings from the present study contribute to our understanding as to how neurons are
protected in the cochlea via the IGF-1 pathway.
HRT and the FoxO3 Cell Cycle Biomarker
Based on the results of this study, FoxO3 does not play a vital role in the preservation of the
cochlea during hormone therapy compared to IGF-1R. HRT SVK-1 cells had FoxO3 gene expression
levels that were notably lower than control, untreated cells throughout the experiment. A parallel trend in
gene expression changes was observed at different time points. For instance, E treated cells had FoxO3
levels that increased to 3.06 at 24 hours and then drastically declined to 0.93 at 72 hours. Similarly, this
pattern was observed in both P and E+P SVK-1 cell groups. However, E+P had slightly higher FoxO3
levels than P treated cells, contrary to what was observed with IGF-1R levels. For instance, the highest
FoxO3 fold expression observed in P treated cells was 1.91; meanwhile, E+P’s highest expression was
2.42; where both of these values were seen at 24 hours. Towards the end of the experiment (72 hours),
the gene expression among all of the hormone groups was relatively similar.
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In vivo experiments

generated analogous results, where no significant differences were seen in FoxO3 fold expressions among
the subject groups 1 month after HRT was discontinued. A possible explanation as to why this occurred
is that FoxO3 levels abruptly declined after 24 hours and continued to for the remainder of the
experiment. Apparently, the effects of HRT were irreversible since FoxO3 levels never increased once
treatment ended.
Surprisingly, the up/down regulation of FoxO3 levels observed in SVK-1 cells did not mirror the
results of the DPOAE thresholds and amplitude levels I obtained during HRT in vivo for this particular
study. That doesn’t mean, however, that changes didn’t take place in cochlear cells during treatment.
FoxO3 is heavily regulated by the phosphorylation of AKT based on environmental conditions.
Untreated SVK-1 cells had qPCR values of 0.86 and 3.14 for IGF-1R and FoxO3 expression levels,
respectively.

All of the cells that were administered HRT had FoxO3 levels that displayed lower

expression values than control cells, most significantly at 72 hours. IGF-1R levels, on the other hand,
continually increased for hormone treated cells over the course of the experiment. It is possible that the
up-regulation of IGF-1R, led to the down-regulation of FoxO3 in the cochlea, as a contemporary
response. For instance, a study that was performed using MCF-7 cells discovered that IGF-1R expression
increased with incremental dosages of E; however, FoxO3 levels remained the same after 10 nM and 100
nM of E treatment (Olivieri et al., 2014). It is possible that the vast proliferation of IGF-1R in SVK-1
cells could have activated another signaling pathway to prevent apoptosis from occurring without the
need to up-regulate FoxO3.
Interestingly, nuclear factor kappa B (NF-κB), a substrate associated with the PI3K/AKT
pathway, has been linked to the IGF-1 pathway and plays a role in the regulation of age-related
degenerative diseases via the transcription of anti-apoptotic genes such as cIAP1 and cIAP2 (Salminen &
Kaarniranta, 2010; Vasudevan & Garraway, 2010). A pioneering study by Bertrand and colleagues
(1999) demonstrated that insulin/IGF-1 activated the NF-κB system in Chinese hamster ovarian (CHO)
cells through the expression of TRAF2 and Mn-SOD; therefore, reducing the chances of apoptosis—
programmed cell death. This research team also discovered a feedback loop system that was activated by
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TRAF2 to induce apoptosis, which was inhibited by IκB-α.

Additionally, Mitsiades et al. (2002)

demonstrated that IGF-1 steadily activated NF-κB as well as AKT, which mediated the up-regulation of
anti-apoptotic genes, such as FLIP and cIAP2, in multiple myeloma (MM) cells. There are conflicting
theories, however, as to whether NF-κB is truly activated by insulin/IGF-1. For example, even though
Barber et al. (2001) showed that IGF-1’s ability to prevent apoptosis was compromised when neonatal rat
retina cells (R28) cells were treated with SN50M (a peptide inhibitor for NF-κB), the study concluded
that NF-κB may not specifically rescue R28 cells from apoptosis due to SN50M’s ability to “block other
transcription factors with nuclear localization by competing for binding to components of nuclear
transport machinery” (Barber et al., 2001).
For this present study, the increase of IGF-1R could have promoted the down-regulation of
FoxO3 in order to activate NF-κB signaling via the PI3K/AKT/NF-κB pathway (Refer to Figure 28). For
example, some previous studies have shown that FoxO3 can inhibit NF-κB signaling (Salminen &
Kaarniranta, 2010). So, instead of cells being protected by FoxO3’s ability to inhibit the transcription of
pro-apoptotic genes, HRT SVK-1 cells were potentially safeguarded by NF-κB’s transcription of antiapoptotic genes. The fact remains, however, that AKT has access to numerous substrates (i.e., glycogen
synthase kinase-3, caspase-9, etc.) that all contribute to cell survival and can modulate programmed death.
Therefore, more research should be done to confirm which related cell signaling pathways are activated
by IGF-1R for the PI3K/AKT pathway to prevent apoptosis. In conclusion, the findings from my study
suggest that FoxO3 is not a primary gene that is activated by AKT to induce cell survival in cochlear cells
during HRT treatments.

Summary
The current investigation demonstrated that female sex hormones, E in particular, regulate IGF1R and, to a lesser extent, FoxO3 expression via the PI3K/AKT pathway in the mammalian cochlea to
promote sensory cell health, and delay certain key aspects of ARHL. These hormones appeared to have
long-lasting effects on both IGF-1R and FoxO3 expression levels. Specifically, I observed this when E!
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treated SVK-1 cells (in vitro) had levels of IGF-1R that continuously increased over the course of 72
hours of HRT. IGF-1R levels remained high in SV tissue samples (in vivo) that were extracted from Etreated animals 1 month after treatment was discontinued. Conversely, E+P treated cells had lower IGF1R gene expression levels compared to E and P treated cells, most notably at 72 hours of hormone
treatment when the expression declined. Similar results were seen in SV tissue samples for E+P animals.
Additionally, E-treated SVK-1 cells displayed a significant decline in FoxO3 levels during the 72 hour
time lapse of hormone treatment. Analogous results were seen for the in vivo experiments with SV tissue
samples; where the E animal group exhibited lower FoxO3 levels compared to P and E+P animals.
DPOAE results from this investigation as well as my ABR findings (Refer to Chapter 3 above) support
the idea that E improves auditory function, while the combination treatment has the opposite effect.
FoxO3, on the other hand, may not play a substantial role in the auditory system during hormone therapy
due to the fact that expression levels were generally lower than untreated cells for the entire experiment.
For instance, no significant changes were detected among the hormone groups at 72 hours. Comparable
results were observed in vivo for post-treatment animals. In conclusion, my findings suggest that HRT
with E activates IGF-1R in the PI3K/AKT pathway, which stimulates an anti-apoptotic cell signaling
system, somewhat independent of FoxO3, in order to promote cell health and survival in the aging
mammalian cochlea.
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CHAPTER FIVE
SUMMARY AND CONCLUSIONS
Overall, new relationships between HRT and the auditory system have been discovered. Phase I
experiments illustrate how E delays the onset of ARHL with relative decreases in ABR thresholds and
preservation of ABR GIN amplitude levels over a period of 6 months. Interestingly, animals treated with
P showed a notable 10 dB increase in ABR thresholds after 3 months of treatment. Auditory function
continued to worsen as demonstrated by the steadily declining P1 and P4 ABR GIN amplitude levels for
P-treated animals over the course of the experiment. Significant differences were observed at 6 months
and for the recovery period for P1 and P4, respectively. Additionally, P4 amplitude levels for P animals
slightly worsened once treatment was discontinued.

Similar to the P group, E+P animals’ ABR

thresholds significantly increased by 10 dB after 3 months of HRT, remained relatively the same at 6
months, and then increased further during the recovery period. Consistent with the threshold elevations,
ABR GIN amplitude levels for E+P animals sharply declined after 3 months of treatment for P1 and P4.
P4 amplitude levels for this group worsened during the recovery/washout period. Pb animals had the
worst auditory function among the female groups for both ABR thresholds and ABR GIN amplitude
levels. This could be attributed to age as well as lack of E, since the animals were ovariectomized. The
male control group showed signs of ARHL during the course of the experiment; however, not quite as
severely as the Pb and P female groups. Furthermore, there were no substantial signs of recovery
observed for any of the HRT groups. This suggests that side effects of long-term HRT are permanent.
Therefore, women should take precaution, and fully consider the quantities, durations as well as all the
benefits and side effects (such as hearing loss) when deciding whether HRT is the right choice for them.
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Phase II experiments continued to expand on the electrophysiological results from Phase I as well
as Phase II DPOAE findings. The most common theory that explains how E improves auditory function
is its role in regulating neuronal growth and survival. Previous studies have found that E and IGF-1 work
together to promote cell angiogenesis properties to preserve and repair cells after undergoing oxidative or
other stressors. A main purpose for the present investigation was to further explain E’s neuro-protective
properties involving the PI3K/AKT/FoxO3 pathway in cochlear cells, more specifically in the SV. This
was the first multidisciplinary study to evaluate both IGF-1R and FoxO3 gene expression stimulated by
HRT in the auditory system, from both in vitro and in vivo perspectives. In vitro experiments displayed
higher IGF-1 expression levels for E treated cells, compared to the P, E+P and control SVK-1 cells.
Similar results were obtained for in vivo studies were E had significantly higher IGF-1R levels than the
rest of the subject groups. Additionally, IGF-1 serum levels were higher for E (and P) treated animals.
The results from the IGF-1R molecular biology experiments were consistent with my neurophysiological
findings (ABR, ABR GIN, DPOAE results), with E-treated animals having lower thresholds and higher
amplitudes compared to the rest of the subject groups. This further supports the theory that there is cross
talk between the ERβ and IGF-1R biomarkers, since both receptors appear to trigger anti-apoptotic
responses in the cochlea. Contrarily, FoxO3 didn’t seem to play a substantial role in neuro-protection in
cochlear cells, with FoxO3 expression levels lower than control cells for the entire in vitro experiment.
Indeed, at 72 hours, there were no significant differences observed among the HRT cell groups for
FoxO3. In vivo experiments generated parallel results for post-treatment animals. Therefore, hormone
therapy may lead to the down regulation of FoxO3 levels in the SV, as part of a compensatory chain of
molecular pathway events; so together these findings suggest that FoxO3 may not contribute to neuroprotective properties that are detected in the peripheral auditory system during HRT. Furthermore, it is
possible that IGF-1R activates another substrate, such as NK- κB, in the PI3K/AKT pathway to maintain
the health and integrity of aging cochlear cells.
In closing, the findings from my investigation display some of the benefits of E in the auditory
system as well help to explain this hormone’s role in neuro-protection via the PI3K/AKT pathway.
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Understanding how sex hormones influence auditory function will help menopausal women who are
considering HRT to make more informed decisions that best suits their needs, enhance therapeutic options
for ARHL, and possibly lead to more successful research about the relations between hormone levels and
other neurodegenerative diseases or dementias, such as Alzheimer’s disease, which have been associated
with presbycusis.
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APPENDIX A
SUPPLEMENTAL DATA
Table A.1. ABR statistical differences among the HRT groups.

!!
Frequency
(kHz)

3

6

12

16

20

24

32

36

!

Baseline vs. 3 Months
E: ns
P: ns
E+P: ns
Pb: *
Males: ns
E: *
P: ns
E+P:
Pb: **
Males: *
E: ns
P: ns
E+P: ns
Pb: ns
Males: ns
E: ns
P: ns
E+P: ns
Pb: ns
Males: ns
E: *
P: ns
E+P: ns
Pb: ns
Males: ns
E: ns
P: ns
E+P:
Pb: ns
Males: ns
E: ns
P: **
E+P: ns
Pb: ns
Males: ns
E: ns
P: **
E+P: ns
Pb: ns
Males: ns

Baseline vs. 6 Months
E: ns
P: ns
E+P: ns
Pb: ***
Males: ns
E: ns
P: *
E+P: ns
Pb: **
Males: *
E: ns
P: *
E+P: ns
Pb: ns
Males: ns
E: ns
P: *
E+P: ns
Pb: *
Males: ns
E: ns
P: **
E+P: ns
Pb: **
Males: ns
E: ns
P: **
E+P: ns
Pb: ***
Males: ns
E: ns
P: ***
E+P: ns
Pb: ***
Males: ns
E: ns
P: *
E+P: ns
Pb: **
Males: ns

95

Baseline vs.
Recovery
E: ns
P: ns
E+P: ns
Pb: ***
Males: ns
E: ns
P: ****
E+P: ****
Pb: ***
Males: *
E: ns
P: **
E+P: **
Pb: ****
Males: **
E: ns
P: **
E+P: *
Pb: ****
Males: **
E: ns
P: ***
E+P: *
Pb: ****
Males: **
E: ns
P: ****
E+P: **
Pb: ****
Males: ***
E: ns
P: ****
E+P: **
Pb: ****
Males: ***
E: ns
P: ****
E+P: ***
Pb: ****
Males: *

Table A.1. Continued
Frequency
(kHz)

48

WBN

Baseline vs. 3 Months
E: ns
P: ns
E+P: **
Pb: ns
Males: ns
E: ns
P: ns
E+P: ns
Pb: *
Males: ns

Baseline vs. 6 Months
E: ns
P: *
E+P: ns
Pb: *
Males: ns
E: ns
P: ns
E+P: ns
Pb: **
Males: ns

Baseline vs.
Recovery
E: ns
P: ***
E+P: ns
Pb: ***
Males: **
E: ns
P: ****
E+P: ***
Pb: ****
Males: **

Shows the statistical differences among the HRT groups for the ABR thresholds at various checkpoints
the animals were tested throughout the study. Statistical test: 2 way ANOVA followed by Bonferroni;
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
Table A.2. Statistical differences among HRT groups for ABR latency values.
P Group

Male Group

8 kHz
Baseline vs. 6 Months: *
2 kHz
Baseline vs. 6 Months: ****
Baseline vs. Recovery: ****
3 Months vs. 6 Months: ****
3 Months vs. Recovery: ****
8 kHz
3 Months vs. 6 Months: *
6 Months vs. Recovery: ***

Indicates that the P and Male animals had the most statistical differences during the course of the
experiment among the subject groups, specifically at the lower frequency levels. No significant
differences were seen at any of the other frequencies. Statistical test: 2 way ANOVA followed by
Bonferroni; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
Table A.3. Recovery ABR latency values. statistical differences at 2 kHz.
HRT Group Comparison
Statistical Difference
E vs. Pb
**
E vs. Males
****
P vs. Males
***
E+P vs. Pb
*
E+P vs. Males
***
Illustrates the comparisons among the subject groups for ABR latency values during the recovery period
of HRT. All of animal groups display statistical differences at 2 kHz. No significant differences were
seen at any of the other frequencies. Statistical test: 2 way ANOVA followed by Bonferroni; *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001.
!

96

APPENDIX B
ABBREVIATIONS
Auditory Brainstem Responses .................................................................................................. ABR
Age-Related Hearing Loss ...................................................................................................... AHRL
Protein Kinase B............................................................................................................ AKT or PKB
Brain Derived Neurotropic Factor............................................................................................BDNF
Distortion Product Otoacoustic Emissions ............................................................................ DPOAE
Estrogen ........................................................................................................................................... E
Estrogen Alpha Receptor ............................................................................................................ ERα
Estrogen Beta Receptor .............................................................................................................. ERβ
Combination Treatment .............................................................................................................. E+P
Fork head Transcription Factor ................................................................................................. FoxO
Gap-in-Noise ............................................................................................................................... GIN
Hormone Replacement Therapy................................................................................................. HRT
Inferior Colliculus .......................................................................................................................... IC
Insulin-like growth factor 1 ...................................................................................................... IGF-1
Insulin-like growth factor 1 receptor ...................................................................................... IGF-1R
Inner Hair Cells ........................................................................................................................... IHC
Knock Out .................................................................................................................................... KO
Minimum Gap Threshold .......................................................................................................... MGT
First noise burst ........................................................................................................................... NB1
Second noise burst ....................................................................................................................... NB2
Neural Stem Cells....................................................................................................................... NSC
!
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Noise Floor .................................................................................................................................... NF
Nuclear Factor Kappa B ......................................................................................................... NK-κB
Outer Hair Cells ......................................................................................................................... OHC
Ovariectomized ..........................................................................................................................OVX
Progesterone/Progestin ..................................................................................................................... P
Placebo ........................................................................................................................................... Pb
Phosphoinositide 3-Kinase ......................................................................................................... PI3K
Tyrosine Kinase Receptor .......................................................................................................... RTK
Spiral Ganglion Neurons ............................................................................................................ SGN
Stria Vascularis ............................................................................................................................ SV
Stria Vascularis of a P14 Immortomouse ................................................................................ SVK-1
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